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9ABSTRACT
Age-related macular degeneration (AMD; OMIM # 603075) is an eye disease of the elderly, signs
of which appear after the age of 50. In the Western world it is a leading cause of permanent visual
loss with a prevalence of 8.5% in persons under 54 years of age and of 37% in persons over 75
years of age. Early forms of AMD may be asymptomatic, but in the late forms usually a central
scotoma in the visual field follows severely complicating daily tasks.
Smoking, age, and genetic predisposition are known risk factors for AMD. Until recently no true
susceptibility genes had been identified though the composition of drusen deposits, the hallmarks of
AMD, has suggested that the complement system might play a role in the pathogenesis of AMD.
When four groups reported in March 2005, that, on chromosome 1q32, a Y402H variant in the
complement factor H (CFH) gene confers risk for AMD in independent Caucasian samples, a new
period in the field of genetic research of AMD started. CFH is a key regulator of the complement
system. Thus, it is logical to speculate, that it plays a role in the pathogenesis of AMD.
We performed a case-control association study to analyse whether the CFH Y402H variant contain
a risk for AMD in the Finnish population. Although the population of Finland represents a genetic
isolate, the CFH Y402H polymorphism was associated with AMD also in our patient sample with
similar risk allele frequencies as in the other Caucasian populations. We further evaluated the
effects of this variant, but no association between lesion subtype (predominantly classic, minimally
classic or occult lesion) or lesion size of neovascular AMD and the CFH Y402H variant was
detected. Neither did the variant have an effect on the photodynamic therapy (PDT) outcome. The
patients that respond to PDT carried the risk genotype as frequently as those who did not respond,
and no difference was found in the number of PDT sessions needed in patients with or without the
risk genotypes of CFH Y402H. Functional analyses, however, showed that the binding of C-
reactive protein (CRP) to CFH was significantly reduced in patients with the risk genotype of
Y402H.
In the past two years, the LOC387715/ high-temperature requirement factor A1 (HTRA1) locus on
10q26 has also been repeatedly associated with AMD in several populations. The recent discovery
of the LOC387715 protein on the mitochondrial outer membrane suggests that the LOC387715
gene, not HTRA1, is the true predisposing gene in this region, although its biological function is still
unknown. In our Finnish patient material, patients with AMD carried the A69S risk genotype of
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LOC387715 more frequently than the controls. Also, for the first time, an interaction between the
CFH Y402H and the LOC387715 A69S variants was found.
The most recently detected susceptibilty gene of AMD, the complement component 3 (C3) gene,
encodes the central component of the complement system, C3. In our Finnish sample, an additive
gene effect for the C3 locus was detected, though weaker than the effects for the two main loci,
CFH and LOC387715. Instead, the hemicentin-1 or the elongation of very long chain fatty acids-
like 4 genes that have also been suggested as candidate genes for AMD did not carry a risk for
AMD in the Finnish population.
This was the first series of molecular genetic study of AMD in Finland. We showed that two
common risk variants, CFH Y402H and LOC387715 A69S, represent a high risk of AMD also in
the isolated Finnish population, and furthermore, that they had a statistical interaction. It was
demonstrated that the CFH Y402H risk genotype affects the binding of CFH to CRP thus
suggesting that complement indeed plays an important role in the pathogenesis of AMD.
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1 INTRODUCTION
Life expectancy is continuously rising in the Western world. We all hope that these extra days of
old age would be full of health and capability of managing with daily tasks. Age-related macular
degeneration (AMD) is a leading course of irreversible visual loss in the industrialized countries,
and thus one of the threats for freedom and activity in old age. Neovascular AMD, the most severe
form of AMD, leads frequently to bilateral loss of central vision, which fundamentally troubles
daily tasks, including reading, cooking, and driving a car.
The pathogenesis of AMD has been largely unknown and therefore the choices of preventive and
therapeutic strategies are limited. A strong genetic component in AMD has been established,
suggesting that it is a complex disease, probably several genes and environmental factors predispose
individuals to it and, similarly protect them from it. Therefore, the methods of molecular genetics
that need no prior knowledge of pathogenesis have been applicable. Besides, the results obtained
from these studies have been exceptionally successful in AMD. First, genome wide scans showed
repeatedly linkage to two chromosomal regions 1q32 and 10q26. Focused genotyping of single
nucleotide polymorphisms (SNP) revealed the first real susceptibility gene, complement factor H
(CFH) on 1q32. The Y402H polymorphism of CFH has been significantly associated with AMD in
several populations. CFH plays a fundamental role in the regulation of the complement system,
which is a vital part of innate immunity, and it thus offers a new biological pathway to understand
the pathogenesis of AMD.
The three-year period, in which this study has been mainly performed, has been internationally a
time of significant progress in the genetics of AMD. Since the finding of polymorphism in the CFH
gene, several other susceptibility genes have been reported, probably the most significant of these
being the LOC387715/HTRA1 locus residing on 10q26. In contrast to many other complex diseases
where each genetic variant contributes only to a relatively small percentage of cases this seems not
to be the case in AMD. Namely, the CFH Y402H polymorphism and the LOC387715/HTRA1 locus
appear to explain jointly even 70 % of the AMD cases. Furthermore, a variant in the complement
component C3, a crucial element in the complement system, has also appeared to confer a risk for
AMD, thus further emphasizing the role of the complement cascade in the pathogenesis of AMD.
This study was undertaken to evaluate whether the recently identified candidate genes contain a risk
for AMD also in the Finnish population that has characteristics of genetic isolation. The CFH
Y402H polymorphism was further analysed since it is almost certainly one of the main contributors
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in AMD pathogenesis. Especially, as the polymorphism is located at CRP binding site of CFH it
may thus connect the genetic change with a protein-level risk factor for AMD. It was evaluated
whether the CFH has an effect on lesion characteristics of neovascular AMD or on the outcome of
the photodynamic therapy. In addition, the effects of the CFH Y402H polymorphism on the CFH
protein function were analysed. Finally, the statistical interaction of the CFH Y402H, LOC387715
A69S, and C3 R102G polymorphisms, and smoking was evaluated.
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2 REVIEW OF THE LITERATURE
2.1 DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION
2.1.1 Overview of the anatomy
The retina is a transparent lining of the fundus of the eyeball with several layers of highly
specialized cells, of which the rod and cone photoreceptors capture light rays and convert them into
electrophysiological impulses. The ineer retina is adjacent to the vitreous and the outer retina to the
choroid. The outer retina, the most essential structure in AMD, consists of outer segments of
photoreceptors, retinal pigment epithelium (RPE), and Bruch’s membrane. The RPE is a monolayer
of cuboidal cells, rich of melanosomes from which the name is derived. It has a crucial waste-
disposal function in the phagocytosis of shed photoreceptor outer segments. Bruch’s membrane is a
three-layered membrane under RPE: The innermost elastic layer is between two collagenous layers
which are limited to the RPE basement membrane and to the choriocapillaris endothelial basement
membrane. Both the RPE and Bruch’s membrane play a pivotal role, on one hand as a barrier
between the subretinal space and the choroid, and on the other hand, in the transport of molecules
between these two spaces (Odgen 1994).
The macula, or macula lutea which means yellow spot in Latin, is the central area of the retina,
which is responsible for the central visual field. It is 6 mm in diameter and is located temporal to the
optic disc, and lined with temporal vascular arcades. The cones are the principal type of
photoreceptor cells in the macula with the highest density in the fovea (Ø 1.5 mm), the centre of the
macula and the area of the sharpest vision (Figure 1) (Odgen 1994).
14
Reproduced with permission from Novartis
Figure 1. Anatomic structures of the eyeball (a) and cross section of layers of the eye (b) in the
macula.
a)
b)
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2.1.2 Classification
In early AMD, drusen that are hallmarks of AMD appear between the RPE basal lamina and the
inner collagenous layer of Bruch’s membrane. They are pathological lipoproteinaceous deposits
which are funduscopically seen as yellow or white spots in the macula. The composition of drusen
has been constantly under investigation and they are known to be comprised of many
immunological molecules (Anderson et al. 2002). Drusen are classified according to their
morphology (hard/soft/distinct/indistinct), to their predominant type, to number, to size, to main
location, and to the percentage of area they cover. Pigment epithelial changes are early signs of
AMD, as well. Either hypo- or hyperpigmentation is seen along with drusen (Bird et al. 1995).
Early AMD may proceed to late AMD, but it is not uncommon that a patient with no major signs of
early AMD presents first with late wet AMD. Interestingly, drusen may disappear when early AMD
proceeds to late AMD (Klein et al. 1997, Mitchell et al. 2002a).
Late AMD has two forms, neovascular (exudative/wet/disciform) AMD and central geographic
atrophy (dry late AMD). In wet AMD, vessels grow from the choriocapillaris through abnormal
Bruch’s membrane to the space between the neural retina and the RPE (subretinal space) or
between the RPE and Bruch’s membrane (sub-RPE space) forming neovascular membranes. These
novel vessels easily leak leading to accumulation of fluid and exudates or even haemorrhage in the
subretinal and the sub-RPE spaces. Detachment of the neurosensory retina or the RPE follows. The
final form of neovascular AMD is called disciform macular degeneration, which is characterized by
a scar tissue under the retina.
The early neovascular AMD lesions can further be graded as predominantly classic, minimally
classic, or occult according to fluorescein angiographic pattern, where changes in retinal and
choroidal hemodynamics are analysed. Leakage refers to a presence of fluorescein outside blood
vessels with increasing density in the late phases of angiography. Sometimes the term pooling has
been used to describe increased leakage of fluorescein into delineated anatomical space. Diffuse
leakage to tissues, such as subretinal fibrosis or drusen, is staining. In the window effect an intense
choroidal fluorescence is seen because of atrophy of the RPE. In the classic type, the choroidal
neovascularization (CNV) more predominantly grows to the space between the RPE and the neural
retina. In an angiogram, the classic lesion is seen as a hyperfluoresence with a lacy pattern,
unrelated to the window effect, in the early fluorescein angiogram, and leakage of fluorescein with
indistinct edges in the late phase of angiogram. The occult lesion type grows more frequently to the
sub-RPE-space and shows no or minimal early hyperfluoresence in the early phase, while it
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hyperfluoreseces with indistinct edges, unrelated to the window effect, in the late phase (Macular
Photocoagulation Study Group 1991b, Treatment of Age-Related Macular Degeneration with
Photodynamic Therapy (TAP) Study Group 1999). Frequently, the neovascular lesions consist of
both classic and occult components. In the predominantly classic lesion, the classic component
covers 50% of the total CNV lesion area and in the minimally classic lesion less than 50%
(Blinder et al. 2003). These classifications are used in cases, where the combined classical and
occult CNV lesion covers 50% of the total lesion area. Typically, other lesion components than
CNV are serous pigment epithelial detachment or haemorrhage. Central geographic atrophy, dry
form of late AMD, is characterized by central areas of hypopigmentation or depigmentation or
absence of RPE, in which the underlying large choroidal vessels become visible with the window
effect (Bird et al. 1995). Of all AMD patients, approximately 10 % are suffering from neovascular
AMD, and the rest from early AMD (80%) or central geographic atrophy (10%) (Friedman et al.
2004), but neovascular AMD accounts for the majority (80-90%) of severe visual loss (Ferris et al.
1984).
In this thesis a commonly accepted term “age-related macular degeneration (AMD) ” is used to
cover the spectrum of the disease. “Early age-related macular degeneration” or “late age-related
macular degeneration” are used when referring to different stages of the disease, the former
including drusen and pigment epithelial changes, the latter neovascular (exudative/wet) AMD and
central geographic atrophy (dry late AMD).
2.1.3 Clinical diagnosis
Patients with early AMD are often asymptomatic. Moderate decrease of visual acuity or minimal
distortion may occur, however. In the wet AMD distortion of lines and images (also called
metamorphopsia) is usually the first sign while in initial stages of late dry AMD there may be gaps
in images or the disappearance of letters while reading. At the final stage of both type of late AMD,
there is typically a central scotoma in the central visual field seriously disturbing many essential
daily tasks, including reading a newspaper, preparing meals, driving a car, and recognizing faces of
acquaintance.
Diagnosis of AMD is based on macular findings irrespective of the visual acuity. Biomicroscopy of
the fundus, fundus photographs, fluorescein (FA) and/or indosyanine green (ICG) angiography, and
increasingly, optical coherence tomography (OCT) have been used as diagnostic tools. An Amsler
Grid is especially helpful for patients monitoring vision at home (Figure 2).
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Appearance of Amsler Grid
with normal vision
Appearance of Amsler Grid
with AMD
Figure 2. Patient is asked to stare at the dot in the center of the grid. Wavy lines or missing squares
in the grid suggest irreqularity of the photoreceptor layer, which is typically caused by a wet AMD
lesion.
2.2 EPIDEMIOLOGY
2.2.1 Prevalence and incidence
Age-related macular degeneration is the leading cause of irreversible visual loss in the elderly in the
Western world. While the elderly population is continuously growing in number, AMD is becoming
a remarkable public health problem.
Several population-based studies have been performed to study the actual prevalence and incidence
of AMD. Three major studies, the Beaver Dam Eye Study (BDES) from the US, The Blue
Mountains Eye Study (BMES) from Australia, and the Rotterdam Study (RS) from the Netherlands
have used similar protocols, the Beaver Dam Eye Study and the Blue Mountains Eye Study
protocols’ are almost identical, to evaluate the stage of AMD (Mitchell et al. 1995), which permits
direct comparison of these three studies (Klein et al.1992, Mitchell et al. 1995, Vingerling et al.
1995).
Prevalence rates of early AMD (soft drusen and retinal pigmentary abnormalites) are clearly higher
than the rates of late AMD. In the Beaver Dam Eye Study the prevalence of early AMD was 15.6%
in persons aged 86, which was, nevertheless, higher than in the Blue Mountains Eye Study with a
prevalence of 7.2 %. The authors propose that this might reflect a real difference between the two
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populations, US and Australian, rather than a grading difference (Mitchell et al. 1995). The
prevalence of early AMD increases with age as shown in Table 1.
The prevalence of late AMD (neovascular AMD or central geographic atrophy) in all persons 86
years of age has been fairly similar in these three studies (1.6%, 1.9% and 1.7%, respectively)
(Klein et al. 1992, Mitchell et al. 1995, Vingerling et al. 1995). The same applies to the ratio of
AMD subclasses with 2:1 for neovascular to atrophic AMD (Mitchell et al. 1995). However, in the
age group 55-86, a lower neovascular AMD prevalence (which remained almost unchanged after
adjusting for age and smoking-status) was detected in the Rotterdam study with OR of 3.07 for the
Beaver Dam Eye Study and OR of 2.61 for the Blue Mountains Eye Study when compared to the
Rotterdam study (Smith et al. 2001). The difference may reflect differing environmental or genetic
factors between the European and US or Australian populations. Generally, a steep increase can be
seen after 75 years of age in the prevalence of late AMD with percentages in each age group being:
0.2% (55-64 yrs), 0.9% (65-74 yrs), 4.6% (75-84 yrs) and 13.1% (>85 yrs) (Smith et al. 2001).
In all three studies the incidence of AMD seems also strongly to be influenced by the age of patient
plus the stage of AMD at the baseline. In the Rotterdam Study the maximum 5-year risk of 42%
was for persons 80 years of age who had soft indistinct drusen and retinal pigmentary
abnormalities at the baseline (van Leeuwen et al. 2003b). In the Blue Mountains Eye Study it was
estimated that 20-30% of eyes with late lesions in one eye will also develop late AMD in the second
eye in five years (Mitchell et al. 2002a). However, eyes with only small hard drusen at the baseline
did not develop to late AMD in five years regardless of the area involved (Klein et al. 1997).
In a Finnish population based study of 478 persons aged 70, the prevalence of AMD was as
follows: early AMD 32%, geographic atrophy 5.5% and, exudative AMD 3.8%. The prevalence of
any AMD was 41% which was slightly higher than 37% in patients 75 years of age in the Beaver
Dam Eye Study. In the Finnish study the participants were older (range 70-95 years) than in the
Beaver Dam Eye Study (range 43-86 years) which may explain the minor difference (Laatikainen et
al. 1995).
Seven population-based studies of the prevalence of AMD from the US, Australia and Europe
(Klein et al. 1992, Mitchell et al. 1995, Schachat et al. 1995, Vingerling et al. 1995, West et al.
1997, Friedman et al. 1999, VanNewkirk et al. 2000) were used in a meta-analysis which was
undertaken to estimate the overall prevalence of AMD in the US (Friedman et al. 2004). The
prevalence of late AMD (neovascular AMD or central geographic atrophy) was estimated to be
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1.47% in persons 40 of age and over 11% in persons older than 80 years, which indicates that in
the year 2000 a total of 1.75 million individuals were suffering from central visual loss caused by
AMD in the US and the number is estimated to increase to 2.95 million by 2020 (Friedman et al.
2004). If these estimations are extrapolated to Finnish population, it means roughly that in 2006
over 37 000 persons aged 40 and over 26 000 persons aged 80 years had advanced AMD
(Statistics Finland, Population Structure 29.3.2007;
http://www.stat.fi/tup/suoluk/suoluk_vaesto.html). With the longer life expectancy of Western
populations these figures are quite a challenge for future health care.
Table 1. Prevalence and incidence of age-related macular degeneration (AMD) in the three
population-based studies. Percentages for two age groups and for a total patient material of the
study are presented. Ranges in the age groups differ since prevalences are reported differently.
(Klein et al. 1992, Klein et al. 1997, Klein et al. 2002, Klein et al. 2007, Mitchell et al. 1995,
Mitchell et al. 2002a, Wang et al. 2007a, Vingerling et al. 1995, van Leeuwen et al. 2003b)
BDES n=4926 BMES n=3654 RS n=6251
55-64 75-86 Total 55-64 75-86 Total 55-64  75-84 Total
Prevalence Early AMD 13.8% 29.7% 15.6% 2.6% 15.5% 7.2% * * *
Late AMD 0.6% 7.1% 1.6% 0.2% 5.7% 1.9% 0.2% 3.7% 1.7%
55-64 75-86 Total 60-69 80+ Total 60-64 80+ Total
5-year incidence Early AMD 4.7% 22.8% 8.2% 7.4% 14.8% 8.7% 2.6% 22.5% 7.9%
Late AMD 0.3% 5.4% 0.9% 0.6% 5.4% 1.1% 0.1% 3.4% 0.9%
10-year incidence Early AMD 10.7% 36.7% 12.1% 14.7% 32.5% 14.1% NA
Late AMD 1.0% 9.5% 2.1% 3.0% 24.3% 3.7%
15-year incidence Early AMD 12.7% 24.4% 14.3% NA NA
Late AMD 2.6% 7.6% 3.1%
BDES= Beaver Dam Eye Study
BMES= Blue Mountains Eye Study
RS= Rotterdam Study
*In RS study drusen and pigmentary abnormalities are analysed separately while in BDES and
BMES studies “early AMD” is reported as an entity
NA= Not available
2.2.2 Risk factors
Several factors have been identified as potential risk factors for AMD, the most consistent of these
being age, tobacco smoking (Thornton et al. 2005), and heredity (will be discussed in sections 2.5-
2.6), which have been repeatedly and strongly associated with increased risk of AMD.
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The incidence and prevalence of AMD increases with age (Table 1). In the pooled analysis of the
Beaver Dam Eye Study, the Blue Mountains Eye Study and the Rotterdam Study (14752
participants, aged 43 to 99 years) the prevalence of AMD was 0.2% in persons aged 55 to 64 years
but rise up to 13% in those older than 85 years (Smith et al. 2001). Age (>70 versus 65 years of
age) was a risk factor also in all four case groups of the Age-Related Eye Disease Study (AREDS)
study with ORs of 1.47 (Group 2), 2.80 (Group 3), 3.12 (Group 4) and 4.11 (Group 5) (Age-Related
Eye Disease Study Research Group 2000).
Tobacco smoking, the most significant preventable lifestyle exposure, has been found to increase
the risk for AMD from 1.7 to 3.2 -fold in ever smokers and from 1.9 to 4.5-fold in current smokers
(Smith et al. 1996, Delcourt et al. 1998, Seddon et al. 2006). An increased 5-year incidence of late
AMD was detected when comparing current smokers to never smokers (OR 2.35, p=0.008) or to
past smokers (OR 1.82, p=0.04) (Tomany et al. 2004b). A dose-response relationship has been
found with a 6.5-fold risk for neovascular AMD in persons who have smoked more than 10 pack-
years (Vingerling et al. 1996) when compared to persons who had never smoked. Past smokers´ risk
stayed higher for 20 years after cessation of smoking (Vingerling et al. 1996, Delcourt et al. 1998)
and even passive smokers may have an increased, although not statistically significant, risk
(OR=1.42, 95%CI 0.62-3.26)) of late AMD (Smith et al.1996). Current smokers developed late
AMD at an earlier age than ever smokers or non-smokers (mean ages for cases with incident late
AMD: current smokers: 67; past smokers: 73 and; non-smokers: 77 years) (Mitchell et al. 2002b).
Furthermore, smoking appears to increase the risk of bilateral AMD. The risk of bilateral AMD was
5-fold (OR 5.08, p=0.03) in heavy smokers (median of pack-years 18.5), but quitting smoking more
than 20 years ago decreased the risk of bilateral AMD (OR 0.49, p=0.0004) (Chakravarthy et al.
2007).
At present, the rest of the risk factors are less consistent. Female gender has been associated with
increased risk of AMD in many studies. However, it has been speculated that only population based
studies are reliable in considering this issue since women have a tendency to use health care
services more than men (Evans 2001). From this point of view, in the pooled data of three large
population based studies (Smith et al. 2001), no overall difference between female and male gender
existed (OR 0.95, 0.95% CI 0.70-1.28), though a higher 5-year and 10-year incidence of
neovascular AMD was detected in women in the Blue Mountains Eye Study (Mitchell et al. 2002a,
Wang et al. 2007a).
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Being a member of the white race may predispose people to AMD. Rates of neovascular disease
have been lower in black populations but differences in prevalence of early AMD have not been
that clear (Pieramici et al. 1994, Friedman et al. 1999, Age-Related Eye Disease Study Research
Group 2000). Generally, variations between different ethnic groups do exist, but it would be
challenging to evaluate whether they really represent racial differences rather than differences in
life style factors (Klein et al. 1999a).
Studies of alcohol consumption are conflicting, as well. A protective effect of moderate wine
consumption has been reported (Obisesan et al. 1998), while in a study of female nurses and male
health professionals (Cho et al. 2000) or in the Beaver Dam Eye Study (Knudtson et al. 2007)
evidence of an inverse or positive effect of alcohol was not substantial. However, there was an
increased risk of early and dry form of AMD in a former study among women with two or more
white wine drinks per day (RR 2.03, 95% CI 1.24-3.30) and in a latter study the cumulative 15-year
incidence of geographic atrophy (OR 9.2, 95% CI 1.7-51.2) was increased among heavy drinking
men (four or more drinks daily). No association was found neither with coffee nor caffeine
consumption and early AMD (Tomany et al. 2001).
Several dietary factors have been suggested to have an effect on AMD. The authors of the AREDS
study recommended that zinc and antioxidant supplementation (vitamin C: 500mg, vitamin E:
400IU beta carotene: 15 mg, and zinc: 80 mg) should be considered for persons with intermediate
size drusen, at least one large drusen, noncentral geographic atrophy in one or both eyes, or
advanced AMD or vision loss due to AMD in one eye, based on the finding that persons with these
lesions and supplementation had 25 % reduction in 5-year progression of advanced AMD. The
doses used were 5 to 15 times the daily value but no significant adverse effects were reported,
though the supplementation with beta carotene was not recommended for smokers (Age-Related
Eye Disease Study Research Group 2001). The result was supported by a population based cohort
with even a 35% reduction in incident AMD in cases with above-median dietary intake of vitamins
compared to below-median intake (van Leeuwen et al. 2005). In contrast, the authors of the Blue
Mountains Eye Study reported that high beta carotene intake was associated with an increased risk
of neovascular AMD (also after adjusting the smoking status). However, they found zinc, lutein and
zeaxanthin to have protective effect on AMD (Tan et al. 2007b), which had also been suggested in
an earlier study (Gale et al. 2003).
High total fat and high linolenic acid intake have been associated with increased risk of AMD (Cho
et al. 2001), and high fish consumption by itself (Smith et al. 2000, Cho et al. 2001, Seddon et al.
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2006) or with low linolenic acid intake with decreased risk of AMD (Seddon et al. 2001, Seddon et
al. 2003c). The protective effect of fish (OR 0.61, 95%CI 0.37-1.00) and omega-3 long chain fatty
acid (OR 0.61, 95%0.41-0.90) intake on neovascular AMD was confirmed in a recent AREDS
report (SanGiovanni et al. 2007). Interestingly, a high intake of vegetable, monounsaturated and
polyunsaturated fat may also increase the risk of AMD (Seddon et al. 2001) while no association
between fat intake and AMD was found in a large epidemiolgical study (Heuberger et al. 2001).
Results related to dietary fat have been inconsistent and the same applies to other common
cardiovascular risk factors (except smoking) and the relationship between cardiovascular diseases
and AMD. Hypertension, for instance, has been suggested to increase the risk of AMD in some
(Age-Related Eye Disease Study Research Group 2000, Hyman et al. 2000, Klein et al. 2003, van
Leeuwen et al. 2003a, Hogg et al. 2007), but not in all studies (Klein et al. 1993, Tan et al. 2007a).
Recently, persons with early AMD appeared to have a higher risk of incident stroke (Wong et al.
2006a), and a history of cardiovascular disease (stroke, myocardial infarction or angina) was
demonstrated to predict incident early AMD (Tan et al. 2007a), and neovascular AMD or late AMD
appeared, on the other hand, to increase the risk of incident myocardial infarction (Duan et al. 2007,
Wong et al. 2007). However, in previous reports the associations have been not been quite that clear
(Klein et al. 1999b, Tomany et al. 2004b, Clemons et al. 2005).
Obesity (Hirvelä et al. 1996, Age-Related Eye Disease Study Research Group 2000, Seddon et al.
2003b, Clemons et al. 2005, Hogg et al. 2007) and high cholesterol levels, major cardiovascular risk
factors, have also been associated with AMD. Increased serum high density lipoprotein (HDL)
levels have been related to late AMD both positively (Hyman et al. 2000) and inversely (Tan et al.
2007a). In one report, an increased total serum cholesterol level predicted a higher risk of
geographic atrophy but not neovascular AMD (Tomany et al. 2004b), whereas in the other report
elevated total/HDL ratio was associated with both neovascular AMD and geographic atrophy (Tan
et al. 2007a), and in the third report the highest quartile of serum cholesterol was associated with
neovascular AMD (Hogg et al. 2007). Dietary carbohydrates may also be associated with AMD. In
a study of AREDS patients, patients with higher dietary glycemic index (dGI) had a higher risk for
the progression of AMD. It was estimated that 20% of prevalent cases and in five years, 7.8% of
new advanced AMD cases could be prevented with low dGI-diets (Chiu et al. 2007a, Chiu et al.
2007b).
A high level of C reactive protein (CRP), as an indicator of systemic inflammation, may also be a
risk factor for AMD. Persons with advanced AMD had significantly higher levels of CRP than
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those with no AMD (OR 1.65, CI 95% 1.07-2.55, p=0.02; the highest quartile of CRP versus the
lowest quartile) (Seddon et al. 2004) and high CRP levels predicted progression of AMD to more
advanced forms (RR=2.10, CI 95%1.06-4.18, p=0.046) (Seddon et al. 2005b). On the other hand,
Cardiovascular Health Study showed no assocation between AMD and high CRP levels (McGwin
et al. 2005).
Finally, sunlight exposure has been suggested to play a role in the development of AMD yet several
studies could not have confirmed the sun as a risk (West et al. 1989, Darzins et al. 1997, Delcourt et
al. 2001, Khan et al. 2006). However, in the BDES study, persons who had been exposed to
summer sun more than 5 hours a day (in their teens, 30s and at baseline) had a higher 10-year
incidence of early AMD than those exposed less than two hours. If a person had more than 10 sun
burns in his youth the risk to develop large drusen (250 um) was 2.5-fold when compared to those
who had 1 burns (Tomany et al. 2004a).
2.3 PATHOGENESIS
The pathogenesis of AMD is poorly understood, but it is generally accepted that AMD does not
merely represent a normal aging process. No major single pathogenic cascade has been established
and it is yet to be resolved whether different forms of AMD, neovascular AMD and central
geographic atrophy, represent the outcomes of the same pathogenic process. Of the several theories
of pathological changes, more or less connected with each other, in the outer retina and retinal
pigment epithelium (RPE)- Bruch’s membrane- choriocapillaris complex, the general ones are
presented here, more as a list than a comprehensive theory.
2.3.1 Oxidative stress
Oxidative stress is not suggested only in the pathogenesis of AMD but also in many other age-
related diseases. It refers to cellular damage caused by reactive oxidative intermediates (ROI),
which include free radicals, hydrogen peroxide (H2O2), and singlet oxygen, all involved in oxygen
metabolism of cells and generated in cellular metabolism and photochemical reactions. The main
targets of ROI are cell membranes that contain polyunsaturated fatty acids with double bonds,
which are then exposed to lipid peroxidation (Beatty et al. 2000, Ambati et al. 2003).
Oxidative hypothesis in the pathogenesis of AMD is supported by several facts: 1) The oxygen
metabolism of the retina is one of the most active in the body. 2) The outer segments of
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photoreceptors are rich in polyunsaturated fatty-acids. 3) The retina is exposed to radiation. 4) Free
radicals are generated by RPE in the phagocytosis of photoreceptor outer segments (Beatty et al.
2000, Ambati et al. 2003).
Lipofuscin, a group of lipid and protein aggregates in RPE cells, plays an important role in the
oxidative stress theory. Lipofuscin increases with age and accumulates in the macula, concentrated
especially in the parafoveal ring where the rods are the densest. It is presumably a product of the
incomplete processing of phagocytosized photoreceptor outer segments in RPE cells. Lipofuscin
disturbs RPE function by reducing the phagocytosis capacity, by potentiating phototoxicity and thus
aggravating oxidative damage, and by changing the cell architecture (Beatty et al. 2000, Ambati et
al. 2003). The relevance of oxidative stress in AMD is supported by studies that showed that anti-
oxidant supplementation (vitamin C, vitamin E, beta carotene and zinc) decreases the incidence of
AMD (Age-Related Eye Disease Study Research Group 2001).
2.3.2 Inflammation
Though no clinically visible inflammation can be seen in eyes with AMD, one of the key
pathophysiological mechanism undoubtedly is subclinical, local inflammation. The strongest
evidence comes from the studies of the composition of drusen, the hallmark of AMD, located
between the RPE and Bruch’s membrane. Several studies have identified drusen to contain
inflammatory molecules such as vitronectin, complement components C5 and C5b-9, HLA-DR, and
immunoglobulin light chains (Hageman et al. 2001, Anderson et al. 2002).
Since the early 2000’s (Hageman et al. 2001, Anderson et al. 2002), inflammation and/or immune-
mediated processes with complement activation have been suggested to play a role in drusen
formation. A series of events was suggested to lead finally to the buildup of drusen, with RPE cell
dysfunction as a trigger. Several mechanisms including genetic effects, lipofuscin toxicity and
oxidative injury have been hypothesized to contribute to the RPE pathology. Dysfunction leads to
accumulation of cellular debris between RPE basal lamina and Bruch’s membrane. As a
consequence of failure to dispose of this extra material, a series of suggested inflammatory events
ensues, among others activation of the complement cascade and upregulation of inflammatory
mediators (e.g.cytokines). Proteins and lipids that are involved in the inflammation are encapsulated
with the aforementioned primary RPE debris, thus assisting in drusen formation (Hageman et al.
2001, Anderson et al. 2002). Complement attack induces further damage to bystander macular
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tissues and additional RPE atrophy, photoreceptor degeneration and CNV follows (Gehrs et al.
2006).
2.3.3 Choroidal neovascularization
In neovascular AMD, vessels penetrate abnormally from the choroid through Bruch’s membrane to
the subretinal space. Probably the most powerful inducer of neovascularization is vascular
endothelial growth factor (VEGF), which has also been identified in choroidal new vessels in AMD.
A myriad of the proangiogenetic mediators are known, as well as, local (such as pigment epithelial-
derived factor [PEDF]) or systemic (such as angiostatins) inhibitors of neovascularization. In
exudative AMD the balance between pro- and anti-angiogenetic factors combined with a loss of
integrity of the Bruch’s membrane may favour the growth of new vessels into the RPE and the
subretinal space (Ambati et al. 2003).
2.4 TREATMENT AND PROGNOSIS
2.4.1 Photocoagulation
Until recently the therapeutic options of AMD, not to speak of prevention, have been very limited.
Besides, most of them have been almost exclusively targeted at neovascular AMD.
Laser photocoagulation as a therapy for AMD was first presented in 1980’s but it has proven to
have serious weaknesses. Neovascular membranes are ablated thermally and hence the neuroretina
adjacent to treated lesion is also damaged. Consequently, only extrafoveal lesions (>200 m from
the fovea) can be treated without visual loss. In juxtafoveal (1-200 m from the fovea) and
especially in subfoveal lesions, the scotoma that follows the treatment affects central vision
substantially. Although the prognosis was better than the natural course, the immediate scotoma
was not well accepted by the patient, especially not with recurrence rates of 50% in
photocoagulation treatment (Macular Photocoagulation Study Group. 1991a, Schmidt-Erfurth et al.
2007).
2.4.2 Photodynamic therapy using verteporfin
In photodynamic therapy (PDT), a chemical photosensitizer (verteporfin) is administered
intravenously before non-thermal laser. Light is absorbed by the verteporfin molecules attached to
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endothelial cell walls of neovascular membranes. Subsequent release of free radicals from the drug
leads to damage of endothelial cells and other structures in the neovascular and normal
choriocapillaris vessels. PDT induces photothrombosis of the choroidal neovascularization and the
normal choriocapillaris, followed by a varying degree of recovery and recanalization. (Schmidt-
Erfurth et al. 1994, Kramer et al. 1996, Husain et al. 1999, Schmidt-Erfurth et al. 2000, Schmidt-
Erfurth et al. 2002).
For the Treatment of AMD with Photodynamic Therapy (TAP) study, a patient was eligible if he
had a subfoveal CNV lesion with a classic component with the greatest linear dimension of 5400
mm and visual acuity ranging from 20/40 to 20/200 (TAP Study Group 1999). After two years,
53% of the PDT-treated patients and 38% of the sham-treated patients (p<0.001) had lost less than
15 letters (3 lines). In patients with predominantly classic lesions the corresponding percentages
were 59% and 31% (p<0.001). However, only 8% of patients had gained 15 or more letters at the
two-year follow-up. In the first year the average number of treatment session was 3.4 and in the
second year 2.2 (Bressler 2001). Visual acuity seemed to remain stable between follow-ups at two
years and four years with only 0.4 treatment needed in the fourth year (Bressler et al. 2005).
In the Verteporfin in Photodynamic Therapy (VIP) study, patients with occult-only CNV types were
analysed. At two-year follow-ups, in the PDT-group 55% and in the sham-group 68% lost at least
15 letters (p=0.032), and 29% and 47%, respectively, at least 30 letters (p=0.004) (VIP Study Group
2001). A combination of PDT with intravitreal injection of triamcinolone acetate has also given
favourable results (Arias et al. 2006). Studies on combination therapy of anti-VEGF drugs and PDT
are under way.
2.4.3 Anti-angiogenic therapy
Using PDT, it was possible to slow down or stop the progression of visual decline with
improvement in only 8% (gain of 15 letters or more) of patients (TAP Study Group 1999, Bressler
2001). In this respect, the results obtained with vascular endothelial growth factor (VEGF)
inhibitors have provided better results. At present, three anti-VEGF drugs are available, pegaptanid
(Macugen®), an aptamer, and two recombinant, humanized, monoclonal antibodies, ranibizumab
(Lucentis®) and bevacizumab (Avastin®). Pegaptanid and ranibizumab are approved both in US and
Europe for ocular use while bevacizumab is an off-label drug. They are administered repeatedly
intravitreally, pegaptanid every six weeks and ranibizumab and bevacizumab every four to every six
weeks. Since the lesion size or lesion composition are irrelevant in terms of maintenance of vision
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or vision gain, optical coherence tomography (OCT), not necessarily an angiogram, can be used for
monitoring the treatment response (Schmidt-Erfurth et al. 2007). Results from studies of pegaptanid
have not been as favourable as expected (VEGF Inhibition Study in Ocular Neovascularization
[V.I.S.I.O.N.] Clinical Trial Group et al. 2006). At two years, 59% of eyes that have been treated
with 0.3 mg pegaptanid lost less than 15 letters, the corresponding persentage for PDT monotherapy
being 53%. Thus the effect of six-weekly injections of pegaptanid were not clearly superior to the
effect of the PDT (Schmidt-Erfurth et al. 2007).
In the MARINA study (Rosenfeld et al. 2006) patients with occult or minimally classic CNV
lesions received either ranibizumab or sham injections monthly, and in the ANCHOR study (Brown
et al. 2006) patients with predominantly classic lesions received either ranibizumab injections
monthly or standard care PDT treatment. The MARINA two-year results showed that in the
ranibizumab-group (0.5mg) 94.6% and in sham-group 62.2% lost fewer than 15 letters.
Improvement of visual acuity was seen in 33.8% of the ranibizumab-group (0.5mg) and in 5.0% of
the sham-group. Furthermore, patients in the ranibizumab-group gained 7.2 letters whilst in the
sham group they lost 10.4 letters (Rosenfeld et al. 2006). In the ANCHOR study the results were
similar, all differences in the aforementioned comparisons were also statistically significant (Brown
et al. 2006). The PIER study enrolled all lesion subtypes, but the ranibizumab injections were given
first monthly three times, and then in three months interval. This study has been suggested that
injection every three months may be insufficient (Schmidt-Erfurth et al. 2007).
Bevacizumab is approved for therapy of metastatic colorectal cancer but not for AMD. Because its
molecular structure resembles that of ranibizumab, it is hypothesized to have similar effects. The
low costs of bevacizumab and preliminary promising results in a few studies have made it
attractive, though no prospective randomized studies are available. Its systemic safety is also largely
unknown, and it is reported to cause a mild rise in systolic blood pressure (Schmidt-Erfurth et al.
2007).
2.5 GENETICS
2.5.1 Twin studies and family aggregation analyses
The genetic basis of AMD was first demonstrated 30 years ago (Gass 1973). A clearly higher
concordance rates in monozygotic than in dizygotic twins (Gass 1973, Melrose et al. 1985, Meyers
et al. 1988, Klein et al. 1994, Meyers et al. 1995, Grizzard et al. 2003) in several small studies
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suggested a role of heredity in AMD, which was confirmed in two larger twin cohorts. In a British
study of 226 monozygotic and 280 dizygotic twin pairs, an estimated heritability was 45% (95%CI
35%-53%), most heritable phenotypes being soft drusen (57%; 95%CI 50%-64%) and 20 hard
drusen (81%; 95%CI 77%-84%) (Hammond et al. 2002), while in a US study of 210 monozygotic
and 181 dizygotic twin pairs, estimates of heritability ranged from 46% to 71%, the highest rates
being for advanced AMD (Seddon et al. 2005a). The first study comprised only of early AMD that
may explain differing results in these two studies (Hammond et al. 2002). Family aggregation
analyses have further indicated that genetic factors play a role in the aetiology of AMD. The
prevalence of AMD was higher in first-degree relatives of patients with AMD when compared to
first-degree relatives of controls (OR=2.4, 95%CI 1.2-4.7, p=0.013), with even greater risk in
patients with neovascular AMD (OR=3.1, 95%CI 1.5-6.7, p=0.003) (Seddon et al.1997). In the
population based Rotterdam study an increased risk was detected both for early (OR=4.8, 95%CI
1.8-12.2) and in late AMD (OR=19.8, 95%CI 3.1-126) when relatives of patients with late AMD
were compared to relatives of controls. An earlier onset of disease was also suggested. Lifetime risk
estimate of late AMD was significantly different (p<0.001) for the relatives of patients and for the
relatives of controls, with risk of 50% (95%CI 26-73%) and of 12% (95%CI 2-16%), respectively
(Klaver et al. 1998b).
2.5.2 Molecular genetic studies
The development of molecular genetic methods has made it possible to identify genes for
Mendelian disorders, and increasingly also predisposing genes for complex diseases. In genetic
mapping analyses are made for whether a certain allele of a genetic marker and a disease phenotype
are inherited together. It is based on a phenomenon called linkage. This means that during meiosis
adjacent genetic loci on the same chromosome segregate together and are said to be linked to each
other. On the other hand, if two loci (genetic marker and disease phenotype) are far away from each
other, there is a greater risk of recombination to occur in homologous chromosomes during meiosis
that suggests that a marker and disease are not inherited together i.e. not linked with each other.
Application of genetic mapping does not require any knowledge about the underlying cause of the
disease and can thus be applied to diseases whose biochemical backgrounds are totally unknown.
For genome-wide linkage-analysis, families with two or more affected individuals are collected and
the pedigrees are genotyped with 400-1000 markers. Thereafter, it is statistically determined
whether the marker of some locus is inherited with the disease i.e. is in linkage with the disease
phenotype. In further analysis, regions with evidence of linkage may be fine-mapped with denser
29
maps of markers, either with microsatellite markers and/or with single nucleotide polymorphisms
(SNPs) to define the region of candidate genes more precisely.
Recently, significant advances in the identification of predisposing genes have been made in AMD.
Thus far, a total of 11 genome wide-scans have been performed (Klein et al. 1998, Weeks et al.
2000, Weeks et al. 2001, Majewski et al. 2003, Schick et al. 2003, Seddon et al. 2003a, Abecasis et
al. 2004, Iyengar et al. 2004, Weeks et al. 2004, Santangelo et al. 2005, Barral et al. 2006). Three
studies should not be considered to have used independent samples hence their patient material is
overlapping with earlier studies (Weeks et al. 2004, Santangelo et al. 2005, Barral et al. 2006). It is
noteworthy that in several genome scans the ethnicity of the patients is not clearly stated but
Caucasian origin might be assumed. (Table 2)
In the first scan a small family with 10 affected members with dry form of AMD was analysed
(Klein et al. 1998) whereas the following scans comprised of patients with both dry and wet forms
of AMD (Weeks et al. 2000, Weeks et al. 2001, Majewski et al. 2003, Seddon et al. 2003a, Iyengar
et al. 2004, Abecasis et al. 2004, Weeks et al. 2004, Santangelo et al. 2005, Barral et al. 2006).
Assuming that different forms of AMD have distinct pathogenesis/genetics, the variety of
phenotypes in many scans might have biased the linkage analysis. Some evidence for linkage have
been found in nearly every chromosome, though in most of the scans the LOD (logarithm of odds)
scores for the three best loci have not reached the standard accepted value 3.3 (general pedigrees) or
3.6 (sib-pairs) for significant linkage. Instead, they frequently have reached the suggestive evidence
for linkage with a LOD score 1.9/2.2 (Lander et al. 1995) (Weeks et al. 2001, Majewski et al. 2003,
Seddon et al. 2003a, Abecasis et al. 2004, Iyengar et al. 2004, Weeks et al. 2004, Barral et al. 2006).
However, the most often replicated loci with the strongest evidence of linkage have been on the
long arms of chromosomes 1 and 10 (Weeks et al. 2001, Majewski et al. 2003, Abecasis et al. 2004,
Iyengar et al. 2004, Weeks et al. 2004, Barral et al. 2006), which were confirmed in the meta
analysis of 6 genome scans, as well (Fisher et al. 2005). The strongest evidence for linkage
(p=0.00025) was on chromosome 10q26 while a nominal significance also appears on
chromosomes 1q, 2p, 3p, and 16 (Fisher et al. 2005). In a study of specific chromosomal regions on
1q, 9p, 10q, and 17q, a total of 70 multiplex families (133 affected sib pairs [ASP]) with different
forms of AMD were analysed. Once again the best linkage was identified on chromosome 10q26
with LOD score 1.52 (Kenealy et al. 2004).
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2.5.3 Association studies
Association studies are becoming increasingly useful tools for detecting causal variants of common
diseases. The frequency of alleles in genetic marker/markers (SNP/SNPs) is compared in affected
and unaffected individuals; the collection of family pedigrees is not needed. In association mapping,
two possible ways are available, direct and indirect. For direct analysis to be used, the functional
variant that predisposes individuals to disease has to be known. However, as this situation is rare an
indirect method is more frequently utilized. This is based on a phenomenon called linkage
disequilibrium (LD), which means that a certain haplotype (an array of polymorphisms) has been
inherited together with the disease variant. So, an SNP can be an indicator of the causal gene/SNP
that lies in neighbourhood and will be associated with the disease due to LD (Collins et al. 1997).
The International Hap Map Project, the goal of which is to compare genetic similarities and
differences in human beings, has given tools for genome-wide association analyses by mapping
SNPs in several populations (Nigeria, China, Japan and US). Most recently, The International
HapMap Consortium reported that it has characterized over 3.1 million SNPs that are publicly
available for research community (International HapMap Consortium et al. 2007). In the research of
AMD, linkage analyses have led the way, and later on association analyses were used to detect
susceptibility genes.
2.5.4 Candidate genes
2.5.4.1 Complement system related susceptibility genes
Not surprisingly, in 2005, the first notable susceptibility gene of AMD was found on 1q32, the
region that had been replicated in several genome-wide scans. The finding of Y402H polymorphism
in the complement factor H (CFH) gene was a significant breakthrough not only in the field of
ophthalmic research but also in the field of complex diseases in general. Thus, a full section is
devoted only to the complement system, CFH and other complement system related susceptibility
genes (Section 2.6).
2.5.4.2 LOC387715/HTRA1 locus
When the other major candidate locus on 10q26 was further analysed with focused SNP
genotyping, two adjacent genes were first identified as risk factors for AMD: The hypothetical
LOC387715 gene and the pleckstrin homology domain-containing protein 1 (PLEKHA1) gene
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(Jakobsdottir et al. 2005). Later studies suggested that the T allele of rs10490924 in the LOC387715
gene (other designation ARMS2), resulting in a nonsynonymous A69S change in exon one, is the
causal variant (Rivera et al. 2005, Conley et al. 2006, Schmidt et al. 2006). LOC387715 is a
hypothetical gene with unknown biological function and only weak expression in human tissues.
However, a recent study strengthened the LOC387715 A69S`s role as a possible causal variant of
AMD by demonstrating that LOC387715 mRNA could be found in the human retina and that it
encodes a mitochondrial outer membrane protein (Kanda et al. 2007).
The LOC387715 A69S variant has been shown to confer a risk for AMD both in Caucasian and
Asian populations. The risk allele frequency has reached 36-42 % in Caucasian (Rivera et al. 2005,
Schmidt et al. 2006, Ross et al. 2007, Schaumberg et al. 2007) and 59% in Japanese populations
(Tanimoto et al. 2007). Corresponding percentages for controls have been 19-26% (Rivera et al.
2005, Schmidt et al. 2006, Ross et al. 2007, Schaumberg et al. 2007) and 35% (Tanimoto et al.
2007), respectively. In all these populations the difference in the risk allele frequency between cases
and controls has been highly significant. Interestingly, in the population-based Blue Mountains Eye
Study the risk allele frequency was lower with 27%, which reflects the difference in patient
materials: BMES had more early and intermediate AMD cases than the clinic-based samples (Ross
et al. 2007). Overall, the LOC387715 A69S variant has been associated more often with late AMD
than with the earlier stages (Rivera et al. 2005, Conley et al. 2006, Shuler et al. 2007a, Shuler et al.
2007b). Several studies have also demonstrated an allele-dosage effect in A69S with ORs ranging
from 1.7 to 2.7 for heterozygous (TG) and from 5.7 to 8.6 for homozygous (TT) individuals when
compared to a non-risk genotype (GG) (Rivera et al. 2005, Conley et al. 2006, Schmidt et al. 2006,
Ross et al. 2007). Schmidt et al. (2006) have reported gene-environment interaction between the
LOC387715 A69S and smoking, which has not been replicated since (Conley et al. 2006, Hughes et
al. 2007, Ross et al. 2007, Wang et al. 2007b). Even their own later study failed to demonstrate
interaction, though the study was not aimed at analyzing smoking (Shuler et al. 2007a).
The role of the LOC388715 as a susceptibilty gene on 10q26 has been controversial since
associations that have been found between late AMD and a promoter variant (rs11200683) of the
high-temperature requirement factor A1 (HTRA1) gene (other designation PRSS11) have been
highly significant, as well (Dewan et al. 2006, Yang et al. 2006, Cameron et al. 2007, Lu et al.
2007, Mori et al. 2007b, Weger et al. 2007, Yoshida et al. 2007). LOC387715 and HTRA1 are
adjacent genes, which are in complete linkage disequibrillium, HTRA1 is only 6 Kb downstream
from LOC387715. The HTRA1 promoter variant risk allele A frequency in cases (36-44%;
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Caucasian [Yang et al. 2006, Cameron et al. 2007], 69%; Japanese [Yoshida et al. 2007] and 78%;
Chinese populations [Lu et al. 2007]) and controls (25%; Caucasian [Yang et al. 2006, Cameron et
al. 2007], 32%; Japanese [Yoshida et al. 2007] and 44%; Chinese populations [Lu et al. 2007)]) has
been similar to that of the T allele frequency of LOC387715. The same applies to the differences
between genotypes, which have been highly significant. HtrA1 belongs to the human HtrA family
of proteases HtrA1, HtrA2, HtrA3, and HtrA4. The precise function of HtrA1 is unknown, but some
suggestions of its role in the pathogenesis of various disease have been made: It has been reported
to have a role as a tumour suppressor in ovarian carcinoma (Shridhar et al. 2002) and melanoma
(Baldi et al. 2002), and HtrA1 levels in synovial fluids of patients with osteoarthritis and
rheumatoid arthritis have been 3-7-fold when compared to non-arthritic individuals (Grau et al.
2006). Recently, HtrA1 was detected in mature mucosal human and murine mast cells (Gilicze et al.
2007) and in the pigment retina of mouse embryo (Tocharus et al. 2004), and has been shown to act
as an inhibitor of transforming growth factor  (TGF ) signalling (Oka et al. 2004, Tocharus et al.
2004). HtrA1 has also been detected in the human retina (drusen) of AMD patients (Yang et al.
2006), although Kanda et al. recently showed that rs11200638 did not change the HTRA1 promoter
activity (Kanda et al. 2007). This might once again speak for the fact that rs10490924 of the
LOC387715 gene, not the HTRA1, is the true causal variant of AMD on 10q26.
2.5.4.3 Others
Both positional and functional candidate gene approaches have been used in the research of AMD.
Genes of juvenile macular dystrophies that have similar clinical characteristics with AMD have
been hypothesized as candidates, but this approach has failed. The genes of Best disease or Sorsby
disease could not have been associated with AMD (De La Paz et al. 1997, Allikmets et al. 1999),
and though the ATP-binding cassette (ABC) transporter (ABCA4) gene of Stargardt disease has
been under considerable investigation its role in AMD has not been ascertained. In addition to
positive results (Allikmets et al. 1997, Allikmets 2000, Shroyer et al. 2001), several groups have not
detected any clear association between the ABCA4 gene and AMD (Rivera et al. 2000, Guymer et
al. 2001, Webster et al. 2001, Schmidt et al. 2003). Earlier, variants in the elongation of very long
chain fatty acids-like 4 (ELOVL4) gene on 6q14 have been identified in autosomal dominant
macular dystrophy (Bernstein et al. 2001, Edwards et al. 2001, Zhang et al. 2001, Maugeri et al.
2004), but not in AMD (Ayyagari et al. 2001). When Conley et al. analysed several candidate
genes, they found that a M299V variant in exon 6 of the ELOVL4 gene was associated with AMD
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(Conley et al. 2005), but later studies failed to replicate their finding (Conley et al. 2006, DeAngelis
et al. 2007).
The relationship between the apolipoprotein E (APOE) gene and AMD is also quite controversial.
Allele 2 of the APOE gene at chromosome 19q may be associated with an increased risk and allele
4 with a decreased risk for AMD (Klaver et al. 1998a, Souied et al. 1998, Schmidt et al. 2002, Baird
et al. 2004, Zareparsi et al. 2004), however, results giving no association have also been reported
(Schultz et al. 2003a, Schmidt et al. 2005, Wong et al. 2006b).
After the linkage on chromosome 1q was detected, a sequence variant Q5345R in exon 104 of the
hemicentin-1 gene on 1q31 was identified in a large family with AMD (Schultz et al. 2003b), but
replication has never again been successful (Abecasis et al. 2004, Hayashi et al. 2004, Iyengar et al.
2004, Fuse et al. 2006).
Several other candidate genes (Haddad et al. 2006) have been hypothesized as a risk for AMD
including functional candidates fibulin-5 (Stone et al. 2004), vascular endothelial growth factor
(VEGF) (Haines et al. 2006), and HLA-genes (Goverdhan et al. 2005), as well as, a positional
candidate toll-like receptor 4 gene (TLR4) (Zareparsi et al. 2005b). The individual contribution of
these genes as a risk for AMD appears, after all, to be relatively minor.
2.6 COMPLEMENT SYSTEM
2.6.1 Overview of the complement system
The complement system, comprised of about 35 components in the plasma and on cell surfaces, is a
part of the innate immune system with three main physiologic activities: acting as a host defence
against bacterial infection and as a link between adaptive and innate immunity and having a waste-
disposal function in the clearance of immune complexes and apoptotic cells. In complement
activation, three distinct activation pathways are involved, the classical, mannan-binding lectin and
alternative pathways, all of which converge in the cleavage of C3 to C3b and C3a by a C3
convertase enzyme. Later steps of complement activation (terminal pathway) are similar in the three
pathways leading to formation of the membrane-attack complex (MAC) and to complement-
mediated cell lysis (Figure 3) (Walport 2001).
The classical pathway is initiated when the C1 complex (consisting of one C1q, and two C1r and
C1s molecules) first binds to the antibody-antigen complex on a bacterial cell surface. C1s, an
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active enzyme of the C1 complex, then cleaves C4 and C2, leading to the formation of a C4b2a
enzyme complex, the C3 convertase of the classical pathway. C-reactive protein (CRP), nucleic
acids and damaged cell membranes can also act as activators of classical pathway in the absence of
antibodies (Figure 3) (Walport 2001).
The lectin pathway is initiated by binding of mannan-binding lectin (MBL) to mannose groups on
the surface of a target cell. MBL is associated with two serine protease, MBL-associated proteases 1
and 2 (MASP1 and MASP2). MASP2 acts in a similar fashion to the C1s, leading to the formation
of the C3 convertase enzyme, C4b2a (Figure 3) (Walport 2001).
The alternative pathway is initiated by low-grade cleavage of C3 in plasma and by the covalent
binding of a small amount of C3b to a cell-surface. The environment of the surface on which C3b is
deposited determines whether factor B, a protein homologous to C2, or complement factor H
(CFH), which is a regulator of the complement pathway, binds to C3b. On microbial surfaces,
factor B binds to C3b with a higher affinity than CFH. Factor B, when bound to C3, is further
cleaved by factor D to Bb and Ba. The formed C3bBb complex is the alternative pathway C3
convertase. Properdin stabilizes this enzyme. The C3 convertase enzymes cleave many molecules of
C3 to C3b, which initiate the formation of the membrane-attack complex. On host cell surfaces
polyanions such as sialic acid or glycosaminoglycans favour the binding of CFH, instead of factor
B, to C3b. CFH binds to C3b and acts as a cofactor to factor I, which cleaves C3b into an inactive
product, iC3b. The iC3b can no longer participate in the formation of the C3 convertase enzyme.
Thus, the terminal steps leading to the MAC formation are interrupted (Figure 3). Normally,
complement activity is under strict control with the defence against invading organisms and the
control of excess attack against host tissues in fine balance (Walport 2001).
Disturbances in complement regulation may lead to “innate autoreactivity” which means an attack
against self-tissues in the absence of a specific autoimmune response (Meri 2007). Examples of
diseases with complement autoattacks are hereditary angioedema and paroxysmal nocturnal
hemoglobiuria as well as two rare kidney diseases with acute renal failure; membranoproliferative
glomerulonephritis type II (MPGNII) and recurrent atypical hemolytic uremic syndrome (aHUS).
The cause of latter two diseases is complement factor H (CFH) deficiency or mutation, which lead
to excessive consumption of C3 and thus to severe depletion of plasma C3 (MPGNII) or to a
misdirected complement attack against blood vessel endothelia and blood vessels (aHUS) (Meri
2007). Interestingly, patients with MPGNII develop drusen at young age, the composition and the
structure of which are generally similar to that in patients with AMD (Mullins et al. 2001).
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Figure 3. Complement activation pathways. Enzymatic activity is indicated by broken arrows.
MASP= mannan-binding lectin-associated proteases, MBL=mannan-binding lectin; CFH=
complement factor H; FI=factor I; D=factor D; B=factor B, P=properdin, MAC=membrane attack
complex.
2.6.2  Complement factor H
2.6.2.1 Biological function
CFH is a multifunctional glycoprotein, predominantly synthesized in the liver. It plays a vital role in
the protection of host cells from inappropriate attack of complement by regulating of the alternative
pathway in the fluid-phase and on cellular surfaces. CFH consists 20 repetitive units of 60 amino
acids called short consensus repeats (SCRs). Each of the 23 exons of CFH gene encodes for a single
SCR, except for SCR 2, which is encoded by exons 3-4. In addition, exon one encodes a signalling
peptide and exon 10 is utilized only in factor H-like (FHL)-1 transcript. The complement regulatory
functions, decay acceleration, and cofactor activity, are located in N-terminus of the protein, in SCR
1-4. The C-terminus also contributes to the host protection function on cell and tissue surfaces
(Hellwage et al. 2002, Jozsi et al. 2007) (Figure 4).
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CFH plasma levels vary significantly (110-615 ug/ml) in the population, representing the combined
effect of genetic and environmental factors (Rodriguez de Cordoba et al. 2004). Levels have been
shown to decrease in smokers and to increase with age (Esparza-Gordillo et al. 2004).
2.6.2.2 Factor H protein family
Factor H family is comprised of eight proteins with common structural elements (Figure 4). Their
genes are all located on the Regulators of Complement Activation (RCA) gene cluster on
chromosome 1q32 (Rodriguez de Cordoba et al. 2004). In addition to CFH, factor H-like (FHL-1)
protein and factor H related (FHR) proteins FHR1-FHR5 belong to this family. FHL-1 represents an
alternative spliced product of the CFH gene with its complement regulatory activity. In its N-
terminal it has seven SCRs identical to CFH SCR 1-7 and in the C-terminal end four unique amino
acids. Five FHR genes possess high sequence homology with CFH and are, in all likelihood,
duplications of a common ancestor (Zipfel et al. 2002). The precise functions of products of these
five genes are poorly understood though the high sequence homology with CFH suggests common
functions (Figure 4).
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Figure 4. The complement factor H (CFH) family. Genes of the complement factor H family, CFH
and five complement factor H related (CFHR) genes, are located in the Regulators of Complement
Activation (RCA) cluster on chromosome 1q32. Factor H-like 1 (FHL-1) protein is a product of
alternatively splicing of the CFH gene, and FHR4A and FHR4B are products of alternatively
splicing of the CFHR4 gene (Jozsi et al. 2005). CFH is composed of 20 consecutively numbered
short consensus repeats (SCR). A schematic structure of complement factor H, FHL-1, and factor H
related (FHR) proteins and localization of functional domains in each of them are shown, SCRs
aligned according to the highest homology with SCRs of CFH. The interaction sites with C3,
heparin (Hep), C-reactive protein (CRP), and the streptococcal M protein (M) are indicated. The
CFH Y402 polymorphism is located in SCR domain number 7.
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2.6.2.3 CFH Y402H association studies
Four independent groups reported in early 2005 that a 1277T>C change, resulting in the substitution
of tyrosine to histidine, in exon 9 (SCR 7) of the complement factor H (CFH) gene was associated
with AMD (Edwards et al. 2005, Hageman et al. 2005, Haines et al. 2005, Klein et al. 2005). The
starting points for three of the studies (Edwards et al. 2005, Hageman et al. 2005, Haines et al.
2005) were genome-wide linkage-analyses where a consistent linkage on 1q25-32 had been found.
Then, SNPs flanking only this region were selected. Hageman et. al even narrowed their study to
only complement factor H gene, a probable candidate gene, located in that region. In the fourth
study a whole-genome association study was performed (Klein et al. 2005). Regardless of the
research frame, all the groups concluded that CFH Y402H was highly significantly associated with
AMD.
Since then, the finding has been confirmed in several studies and populations (Conley et al. 2005,
Rivera et al. 2005, Souied et al. 2005, Zareparsi et al. 2005a, Baird et al. 2006, Conley et al. 2006,
Kaur et al. 2006, Lau et al. 2006, Magnusson et al. 2006, Sepp et al. 2006, Simonelli et al. 2006,
Narayanan et al. 2007, Tedeschi-Blok et al. 2007) with relatively similar allele frequencies in many
Caucasian populations. In contrast, the frequencies of the risk allele C have been lower in Japanese
(Fuse et al. 2006, Gotoh et al. 2006, Okamoto et al. 2006, Uka et al. 2006), Chinese (Chen et al.
2006, Lau et al. 2006) and Hispanic populations (Tedeschi-Blok et al. 2007) (Table 3 and Figure 5).
Despite lower risk allele frequency, an association between the CFH Y402H polymorphism and
AMD has also been found in Chinese population (Lau et al. 2006).
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Figure 5. Allele frequencies of the Y402H polymorphism of the complement factor H gene in
different populations. Frequencies of the risk allele C are presented in cases with age-related
macular degeneration and in healthy controls. C-allele frequencies in Japanese, Chinese and
Hispanic populations are notably lower than in Caucasian populations.
CFH Y402H polymorphism has been associated with all forms of AMD: early AMD (Baird et al.
2006, Conley et al. 2006, Despriet et al. 2006, Magnusson et al. 2006, Postel et al. 2006,
Schaumberg et al. 2007, Zareparsi et al. 2005a), central geographic atrophy (Zareparsi et al. 2005a,
Baird et al. 2006, Conley et al. 2006, Magnusson et al. 2006, Postel et al. 2006), and neovascular
AMD (Zareparsi et al. 2005a, Baird et al. 2006, Conley et al. 2006, Lau et al. 2006, Magnusson et
al. 2006, Postel et al. 2006, Schaumberg et al. 2007), though in some studies the effect has been
stronger in late AMD than in early AMD (Baird et al. 2006, Despriet et al. 2006, Francis et al.
2007). Subphenotype analysis of neovascular AMD (predominantly classic, minimally classic and
occult) by two groups has suggested that the CC genotype of the CFH Y402H polymorphism is
associated with predominantly classic CNV lesion configuration (Brantley et al. 2007a,
Wegscheider et al. 2007), while no statistically significant association between neovascular lesion
size and genotype was detected (Brantley et al. 2007a).
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2.6.2.4 Functional analyses
Identification of CFH and other complement components in ocular tissues have provided further
evidence of CFH´s role in the pathogenesis of AMD. Repeatedly, drusen deposits, the hallmark
feature of AMD have been shown to contain CFH amongst other complement proteins including
C3b and MAC (Anderson et al. 2002, Hageman et al. 2005, Donoso et al. 2006). Furthermore, in
human and mouse ocular tissues, CFH has been detected in the distal optic nerve, the sclera, the
RPE-choroid, the retina, the lens, and the ciliary body, and in mouse eyes CFH levels have shown
an increase with age (Mandal et al. 2006). Recently, when CFH-deficient (cfh-/-) mice were
compared to age-matched normal mice, they showed significantly reduced visual acuity and
anomalies in electroretinography. Moreover, in their neural retina accumulation of C3 was detected
(Coffey et al. 2007).
The CFH Y402H polymorphism is in exon 9 that codes SCR domain 7, which has binding sites for
C-reactive protein (CRP) (Jarva et al. 1999), heparin (Meri et al. 1990, Blackmore et al. 1996) and
streptococcal M-protein (Horstmann et al. 1988, Blackmore et al. 1998) (Figure 4). Thus, CRP
would easily offer a link between CFH Y402H polymorphism and AMD. CRP levels of patients
with AMD have been shown to be elevated (Seddon et al. 2004, Seddon et al. 2005b), and
individuals with homozygous (CC) risk genotype of CFH Y402H had 2.5-fold levels of CRP in the
choroidal stroma when compared to TT non-risk individuals. It should be noted, however, that this
difference was independent of disease status (Johnson et al. 2006). A haplotype in the CRP gene
that is associated with increased serum CRP levels also increased the risk of AMD in the CC
individuals but not in the TT individuals (Despriet et al. 2006). Reduced binding of CRP, as well as
heparin and RPE cells by CFH, was detected in CFH heterozygous CT and homozygous CC risk
variants (Skerka et al. 2007), but the binding of C3b was similar, irrespective of genotype. In this
study the difference was also seen in FHL-1, which also possesses the SCR7, where the
polymorphism is located (Skerka et al. 2007).
2.6.2.5 Gene- gene and gene- environment interactions
With regard to the nature of complex diseases, several gene-gene and gene-environment
interactions are assumed to be involved in their pathogenesis. These interactions can be approached
by statistical and cell biological methods. Statistically, the degree of biological interaction of the
susceptibility genes and environmental risk factors can be assessed by the departure-from-additivity
model (Andersson et al. 2005). In this model, it is assumed that odds ratios can be used in lieu of
relative risks. Relative risk due to interaction (RERI), attributable proportion due to interaction (AP)
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and, synergy index (S) can be calculated by an Excel program freely available on the Internet
(www.epinet.se). The regression coefficients (odds ratios) received from logistic regression model
are exploited in the calculations. If no statistical biological interaction exists, RERI and AP are
equal to 0 and S equal to 1 (Andersson et al. 2005). Detecting a biological interaction of two factors
means that at least one pathophysiological pathway towards disease exists, where both of the risk
factors play a role. A statistical interaction can be evaluated by the logistic regression model
(departure-from-multiplicative model).
In AMD, it is attractive to hypothesize whether the two most consistently replicated risk factors,
smoking and CFH Y402H, could turn out to be related to a common pathogenetic mechanism.
Especially, because smoking itself decreases CFH plasma levels (Esparza-Gordillo et al. 2004).
However, smoking and CFH Y402H have appeared independently to increase statistically the risk
of all forms of AMD (Sepp et al. 2006, DeAngelis et al. 2007, Scott et al. 2007). In a population
based material, a suggestive biological interaction was detected between smoking and Y402H.
Current smoking alone increased the risk of AMD to 3.4-fold, carrying both risk alleles of CFH
Y402H to 12.5-fold, and the combination of current smoking and the homozygous risk genotype to
34-fold (Despriet et al. 2006).The association analyses have indicated that the LOC387715 A69S
and CFH Y402H variants have independent effects on AMD (Rivera et al. 2005, Conley et al. 2006,
Maller et al., 2006, Schmidt et al. 2006).
2.6.2.6 Other variants of the complement factor H gene
Already in their first study of CFH Y402H polymorphism, in 2005, Hageman et al. (Hageman et al.
2005) reported other AMD-associated variants, as well. They used eight SNPs in their haplotype
analysis and found one common risk haplotype H1 (OR 2.46, p<0.00001) and two protective
haplotypes, H2 (OR 0.54, p=0.00003) and H4 (OR 0.48, p=0.00008). Li et al. reported 20 SNP out
of 84, they examined in and around the CFH gene, possessing stronger association with AMD than
the Y402H polymorphism. In addition, they found two susceptibility and two protective haplotypes
(5-SNP haplotypes). The frequency of protective haplotype 1 was 14% in cases and 44% in controls
and the frequency of haplotype 2 was 3% in cases and 11% in controls (Li et al. 2006). An Indian
study, in which haplotype block consisted of 6 SNPs, revealed a risk haplotype, similar to the H1 in
the study of Hageman et al., and a protective haplotype, similar to the H2 in the study Hageman et
al. (Hageman et al. 2005, Kaur et al. 2006). The presence of two protective haplotypes, again
similar to those in the study of Hageman et al. (H2 and H4), was confirmed in a family-based
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dataset. Moreover, an interaction between smoking and one of the protective haplotype (H4 in study
of Hageman et al.) was suggested (Spencer et al. 2007b).
Most recently, an association study of three different patient samples (familial AMD cases, sporadic
advanced AMD cases and cases from AREDS study) showed, in addition to Y402H, a highly
significant association between a synonymous A473A (rs2274700) polymorphism in exon 10 and
AMD. A haplotype containing this polymorphism, Y402H, and A307A in exon 7 was also
significantly associated with AMD (Francis et al. 2007). Though, the CFH Y402H polymorphism is
not a risk factor in the Japanese, two SNPs in CFH that are in almost complete LD have been
associated with AMD, the aforementioned SNP A473A alongside with intronic SNP (rs1410996)
(Mori et al. 2007a).
In a study of factor H family genes, a novel protective haplotype was detected with a frequency of
20% on chromosomes of controls and of 8% on the chromosomes of patients with neovascular
AMD (Hughes et al. 2006), and with a frequency of homozygous deletion in 5.7% in controls and in
1.1.% in cases with AMD (p=1.6 x 10 -9) (Hageman et al. 2006). This haplotype carries a deletion
of complement factor related (CFHR)1 and CFHR3 genes. In sera of homozygous individuals no
protein coded by these genes could either be detected (Hughes et al. 2006). It was suggested that
FHR1 and FHR3 might interfere with the decay acceleration and cofactor functions of CFH and
lead to the uncontrolled action of complement. Thus, patients with a deletion of FHR1 and FHR3
might have a more unrestricted function of CFH than those with normal FHR1 and FHR3.
Importantly, this deletion and CFH Y402H polymorphism seemed independently to confer a
significant risk for AMD (Hughes et al. 2006).
2.6.2.7 CFH Y402H polymorphism in other diseases
Since inflammation plays an important role in coronary artery disease (CAD) and AMD, and
atherosclerotic plaques and drusen deposits have both been found to contain complement factor H
(Oksjoki et al. 2003, Hageman et al. 2005), it has been reasonable to hypothesize whether the CFH
Y402H polymorphism may also be associated with CAD. In the Rotterdam study, persons carrying
the homozygous risk genotype (CC) of the CFH Y402H polymorphism had a hazard ratio of 1.77
(95% CI 1.23-2.55) for myocardial infarction when compared to non-risk homozygous genotype
(TT), but the risk of heterozygous genotype (CT) was not increased (Kardys et al. 2006). In a recent
report of the Nurses’s Health Study and the Health Professional Follow-up Study, an inverse
association between CFH Y402H risk genotype and CAD was found in women (risk ratio [RR]
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0.51, 95% CI 0.29-0.89) and in persons < 65 of age at onset of CAD (RR 0.30, 95% CI 0.15-0.61),
but not in men or in persons 65 at onset of CAD (Pai et al. 2007). The rest of the studies have
failed to detect any association between CFH Y402H and CAD, ischaemic stroke or venous
embolism (Goverdhan et al. 2006, Zee et al. 2006, Nicaud et al. 2007, Stark et al. 2007). Nor was
the polymorphism associated with common cardiovascular risk factors such as diabetes,
hypercholesterolaemia, hypertension, obesity, smoking or CRP serum levels, in a German study of
patients with a familial background of CAD (Stark et al. 2007). No association between the CFH
Y402H variant and pre-eclampsia was detected in a recent study from Finland (Kaare et al., in
press).
2.6.3 Other susceptibility genes of the complement system
Since the association between CFH Y402H and AMD was found, researchers have logically been
interested in, whether there might be other AMD associated variants in the complement system.
First, an association between AMD and C2 and complement factor B (CFB) genes was found (Gold
et al. 2006). Both genes are located in the major histocompability complex class III region of
chromosome 6, only 500 kb from each other. C2 and factor B are homologous proteins that play a
role in the initial steps of complement pathways, C2 in the classical pathway and factor B in the
alternative pathway (Figure 3). Four protective variants of C2 and CFB that confer significantly
reduced risk of AMD were detected in two independent cohorts: The L9H variant of CFB and the
E318D variant of C2, in strong LD with each other, and the R32Q variant of CFB and the intronic
variant (rs547154) of C2, also in strong LD with each other. Interestingly, it appeared that controls
carrying the CFH risk allele had a high frequency of the protective allele(s) in CFB/C2 (Gold et al.
2006). Later, the inverse associations between AMD and CFB R32Q, CFB L9H and C2 E318D
variants have been replicated (Maller et al. 2006, Spencer et al. 2007a), though after controlling for
age, CFH Y402H, LOC387715 A69S, and smoking in the logistic regression model, the association
of C2 E318D was no longer statistically significant (Spencer et al. 2007a). This might suggest that
complement factor B is the true causal gene in this region.
Most recently, a common polymorphism (rs2230199) in exon three of the complement factor 3 (C3)
gene on 19p13.3 was associated with AMD in two case-control sets (Yates et al. 2007), and
confirmed in a large case-control sample (Maller et al. 2007). C3 is hypothesized to be very well
conserved phylogenetically (Zarkadis et al.2001), and as earlier described, it plays a vital role in the
complement system in all three pathways (Figure 3). Like CFH, C3 has been found in drusen
deposits, in choroid, and in Bruch’s membrane (Anderson et al. 2002, Hageman et al. 2005) of
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human donors, and in the CFH deficient mice, an accumulation of C3 was detected in the neural
retina (Coffey et al. 2007). Cigarette smoke, confirmed environmental risk factor of AMD, activates
complement (Robbins et al. 1991) by possibly modifying the C3 protein (Kew et al. 1985, Kew et
al. 1987). Also, high plasma levels of C3 have been detected in patients with other complex
diseases, such as coronary artery disease, incident diabetes and, metabolic syndrome (Ajjan et al.
2005, Engstrom et al. 2005, van Oostrom et al. 2007).
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3 AIMS OF THE PRESENT STUDY
1. To investigate whether the risk alleles Y402H of the complement factor H gene,
M299V of the elongation of very long chain fatty acids-like 4 gene, or Q5345R of the
hemicentin-1 gene contain a risk for age-related macular degeneration in the
genetically isolated Finnish population.
2. To analyse whether a connection exists between the complement factor H Y402H
polymorphism and the variation in age-related macular degeneration lesion
characteristics in eyes with a recent exudative AMD.
3. To analyse whether the complement factor H Y402H polymorphism might be related
to the outcome of photodynamic therapy in patients with exudative age-related
macular degeneration.
4. To explore the possible functional changes in complement factor H caused by the
Y402H polymorphism.
5. To investigate whether the risk alleles of the complement factor H, LOC387715, and
complement component C3 genes and smoking contain a risk for age-related macular
degeneration in the Finnish population, and whether the polymorphisms of these genes
and smoking might have an interaction.
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4 MATERIALS AND METHODS
4.1 Patient material
The patient material of study I consisted of 335 Finnish patients with AMD attending the
Departments of Ophthalmology of Helsinki (n=203), Oulu (n=10) and Kuopio (n=40) University
Hospitals, or private offices and outpatient clinics (n=82) between 1999 and 2005. Patients with
AMD fell into two groups: sporadic cases, who reported no known relatives with AMD (n=154)
and familial cases, who had at least one close relative with AMD (n=181). Of the familial cases, 66
index patients had a total of 75 affected relatives. A total of 40 index cases from Kuopio University
Hospital were classified as familial cases based on a detailed interview about having relatives with
AMD (these relatives were not included in genotyping).
Two separate control groups were analysed in this study. The “non-AMD group” comprised of 105
Finnish subjects and the “blood donor group” of 350 anonymous Finnish blood donors. The
inclusion criteria for control subjects of the “non-AMD group” were >65 of age with no large
drusen and no or minimal focal pigmentary abnormalities in the macula. In addition, the ocular
media had to be sufficiently clear for fundus photography. Subjects filling these criteria and
attending the Department of Ophthalmology of Helsinki University Hospital or private clinics were
asked to participate in the study as control subjects. In this setting it is not possible to evaluate how
our cases and controls differ from the entire population of AMD patients and subjects >65 years of
age without AMD in Finland. This is less of problem in genetic analyses but we cannot exclude a
possible selection bias in relation to non-genetic risk factors, e.g. smoking. (Figure 6, Table 4).
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Figure 6. Patient material of Studies I-V.
Table 4. Clinical characteristics of the eyes of the patients of Studies I and V, indicated I/V in each
column. For the type of the most advanced AMD lesion, the lesions were graded in the order of
increasing severity: drusen or geographic atrophy not involving the fovea, geographic atrophy
involving the fovea and an acute exudative or a disciform lesion. For bilateral involvement, the
term ‘late AMD’ indicates the presence of geographic atrophy involving the fovea or an acute
exudative or a disciform lesion.
The type of the most advanced AMD
lesion in the eyes of a study participant
                           Geographic atrophy  Acute exudative or Bilateral
Patient group n Age mean (range) Large drusen      involvolving fovea    a disciform lesion late AMD
Sporadic AMD 154/151 75.4 (52.4-88.5)/ 13.0%/12.6% 0.0%/0.0% 87.0%/87.4% 33.8%/33.1%
75.5 (52.4-88.5)
Familial AMD 106/106 76.1(56.3-92.7)/ 16.0%/17.0% 12.3%/12.3% 71.7%/70.7% 42.8%/42.5%
index patients 75.8 (56.3-92.7)
Familial AMD 75/75 77.7 (52.9-91.5)/ 17.3%/17.3% 13.3%/13.3% 69.4%/69.4% 48.6%/48.6%
relatives 77.7 (52.9-91.5)
Non-AMD 105/105 76.9 (66.8-87.7)/ 0.0%/0.0% 0.0%/0.0% 0.0%/0.0% 0.0%/0.0%
controls 76.9 (66.8-87.7)
455 controls
(105 non-AMD controls +
350 blood donor controls)
Studies 1 and 5
71 non-AMD
controls
Study 4
172 patients
with neovascular AMD
with fluorescein angiograms performed
In the Department of Ophthalmology
of Helsinki University Hospital
Study 2
95 patients
with neovascular AMD
treated with photodynamic threrapy
In the Department of Ophthalmology
of Helsinki University Hospital
Study 3
118 Familial cases
Study 4
335 Finnish patients
with AMD
diagnosed 1999-2005
(181 Familial cases + 154 Sporadic cases)
Studies 1 and 5
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Of these 335 cases with AMD, a total of 172 patients attending the retina clinic of the Department
of Ophthalmology, Helsinki University Hospital, for a recent exudative AMD, were enrolled to
Study II. Thus, all the patients of Study II had acute wet AMD lesion. Out of the 172 eyes enrolled,
8 eyes were excluded because more than 50% of the total lesion area consisted of subretinal
hemorrhage. In the remaining 164 eyes the mean age (SD) of the patients was 75.0 (6.6) years. In
patients with bilateral wet AMD, the eye which had been evaluated for the first time for a recent
wet AMD at a date closest to 31 March 2003 was selected as the study eye.
Further, for Study III, we selected 95 patients out of these 172 who had been treated with
photoynamic therapy (PDT) in 1999 -2005 at the Department of Ophthalmology, Helsinki
University Hospital. Seven PDT- treated AMD patients were excluded from the final analysis: Six
patients were scheduled for further PDT sessions and one of the patients had been given an
intravitreal injection of triamcinolone acetonide. The mean age (SD) of these 88 patients was 75.2
(6.4) years. If a patient had bilateral exudative AMD, the eye which had PDT therapy for the first
time at a date closest to 31 March 2003 was selected as the study eye. The final material consisted
of 88 PDT-treated eyes in which no further PDTs were planned.
For Study IV, 118 familial AMD cases seen in the Department of Ophthalmology of the Helsinki
University Hospital were collected from the case sample of Study I. A control group that comprised
of 71 patients was collected from the non-AMD controls of Study I. For CRP-CFH binding studies
a random cohort of 46 AMD patients and 33 control patients was selected out of the original Study
IV patient material. The mean age of the AMD cases was 77.0 (range 58.1-92.4) years and that of
the control subjects 76.6 (range 69.8-87.5) years. Sections of human eyes that were studied were
obtained, stained and analyzed by laser scanning confocal immunofluorescence microscopy as
described by Johnson et al. (Johnson et al. 2006).
In Study V, three patients out of 335 cases of Study I were excluded: There was a genotyping
failure in two of the 154 sporadic cases and one of the sporadic cases was reported to have a novel
AMD case in his family and was thus transferred to the familial group. Of the 181 previous familial
cases, one from Kuopio University Hospital could not be genotyped because of the insufficient
amount of DNA. The final patient material for Study V comprised of 332 Finnish patients with 151
sporadic cases and 181 familial cases. Otherwise the patient material and the controls were the same
as in Study I (Table 4).
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Blood samples for genotyping were obtained from all the patients with AMD and control
individuals. The study was approved by the Ethics Committee of the Helsinki University Eye and
Ear Hospital and performed in accordance with the Declaration of Helsinki. Informed consent was
obtained from all of the subjects after explanation of the nature and possible consequences of the
study.
4.2 Ophthalmologic investigations
For Studies I and V, the AMD stage was verified in the family members of the index patients from
fundus photographs or angiograms in 45 (60.0%) (I and V), from the medical records in 28 (37.3%)
(I and V) and from an examination by a retinal specialist belonging to the study group in two of the
patients (2.7%) (I and V). In the rest of the subjects (index cases, sporadic cases and non-AMD
controls) the AMD stage was verified from fundus photographs or angiograms in 341 (93.4%) (I)/
338 (93.4%) (V), from an examination by a retinal specialist belonging to the study group in four
(1.1%) (I and V), and from medical records in 20 (5.5%) (I and V) of the subjects. A more detailed
description of the AMD stage is given in Table 4.
In Studies II and III visual acuity (VA) assessment, using Snellen or ETDRS (Early Treatment
Diabetic Retinopathy Study) tables and transformed into logMAR values (III), biomicroscopy of the
anterior and posterior parts of the eye, and fluorescein angiography (FA) were performed for all
patients (II and III). The angiograms were recorded using either the Topcon Imagenet (Topcon Inc.,
Tokyo, Japan) or Heidelberg retinal angiograph (Heidelberg Engineering, Heidelberg, Germany)
systems. The area measurements were performed with the software within the respective imaging
systems.
The records and the angiograms of the patients were later reviewed by a retina specialist masked to
the identity and the CFH Y402H genotype of the patients. The following parameters were recorded:
Total lesion area included the occult and classic choroidal neovascular (CNV) lesion components,
serous pigment epithelial detachment (PED), and haemorrhage, dense enough to cover underlying
fluorescence. The CNV lesion area consisted of the classic and occult lesion components but
excluded serous PED and haemorrhage. The presence and size of a serous PED and the presence of
a retinal-angiomatous proliferation (RAP) were also recorded. Only one eye of each subject was
analysed, except for the data presented on the fellow eyes. The choroidal neovascularization (CNV)
category was further classified in to lesions where the CNV lesion was 50% of the total lesion
area. These lesions were graded as predominantly classic, minimally classic or occult according to
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the Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) study
guidelines (TAP Study Group 1999) (II and III).
In the Study III, the patients were classified as “PDT-responders” or “PDT-non-responders” based
on the outcome of PDT after the last treatment session. In the “PDT-responders” the PDT-treatment
was considered to be successful (anatomic response), if the treating physician had deemed the
lesion to be clinically dry without active leakage from CNV in FA at a visit scheduled at least 12
weeks after the last PDT treatment. In the “PDT-non-responders” the PDT sessions had been
discontinued by the treating retina specialist due to a still exudative lesion after several PDT-
sessions. Our clinic is the only referral centre for AMD patients in the district where the patients
came from.
Information about the smoking history of the study participants was obtained by telephone (V). If a
participant has ever smoked, the age at which he started and quit (if he had quit) smoking was
recorded, as well as the number of cigarettes smoked per day during that period. Then, the number
of pack-years was calculated (cigarettes smoked per day X years smoked / 20 [cigarettes per pack]).
A binary variable never/ever was based on the information whether a study participant had smoked
< one pack-year or > one pack-year in his lifetime.
4.3 PCR-sequencing
DNA was extracted from 10 ml of peripheral blood using a phenol-chloroform method. The DNA
of the study subjects was amplified by the polymerase chain reaction (PCR) and sequenced using
primers shown in Table 5 to determine the genotypes. Polymerase chain reaction conditions were as
follows: 5 min at 94 °C followed by 35 cycles of denaturation step: 30 s at 94 °C; annealing step: 30
s at 52-60 °C; elongation step: 45 s at 72 °C; and final extension for 7 min at 72 °C. Sequencing
was performed using cycle sequencing with the Big Dye Terminator kit (version 3.1) supplied by
Applied Biosystems (ABI, Foster City, CA, USA), and reactions were run on an ABI 3730 capillary
sequencer according to the manufacturer's instructions.
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Table 5. Primers for evaluation of variant of the hemicentin-1 gene and polymorphisms of the
complement factor H (CFH), the elongation of very long chain fatty acids-like 4 (ELOVL), the
LOC387715, the high-temperature requirement factor A1 (HTRA1), and the complement factor 3
(C3) genes. Numeral of study is indicated in parenthesis.
Polymorphism Primer sequencies
Hemicentin  Q5345R (I) 5'-cctgtgttttgtgtgtgtatgtatg-3' (F)
5'-gagagcccacagaaaggaaa-3' (R)
CFH Y402H (rs1061170) (I-V) 5'-ctttgttagtaactttagttcg-3' (F)
5'-ttagaaagacatgaacatgctagg-3 (R)
ELOVL4  M299V (rs3812153) (I) 5'-atgcactgggctctaattgc-3' (F)
5'-ccaagctctcctttgcttct-3' (R)
LOC387715  A69S (rs10490924) (V) 5-ggtggttcctgtgtccttca-3 (F)
5-ggggtaaggcctgatcatct-3 (R)
HTRA1  (rs11200638) (V) 5-atgccacccacaacaacttt-3 (F)
5-cgcgtccttcaaactaatgg-3 (R)
C3  R102G (rs2230199) (V) 5-ggaacagacccctgacaatg-3 (F)
5-cttgtggttgacggtgaaga-3 (R)
4.4 C-reactive protein- CFH Y402H protein interaction analyses
4.4.1 Immunohistochemistry
Sections of human eyes were obtained, stained and analysed by laser scanning confocal
immunofluorescence microscopy as described by Johnson et al. (Johnson et al. 2006).
4.4.2 SDS-PAGE and Immunoblotting
To determine whether the CFH Y402H polymorphism influenced the molecular nature of serum
CFH, serum samples from 54 AMD patients and controls either non-risk (genotype TT) or risk
homozygous for CFH Y402H (genotype CC) or heterozygous for the Y402H polymorphism
(genotype CT) were analysed by immunoblotting using polyclonal and monoclonal (86X and 90X)
antibodies directed against CFH (Jokiranta et al. 1996). Serum samples from patients and controls
were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
(Cleveland et al. 1977) under nonreducing conditions. The proteins were transferred onto a
nitrocellulose membrane, and nonspecific binding sites were blocked. Polyclonal goat anti-human
CFH (Calbiochem) or monoclonal antibodies and peroxidase-conjugated donkey anti-goat IgG
(Jackson ImmunoResearch laboratories) or peroxidase-conjugated rabbit anti-mouse IgG (Jackson)
were used for the detection of CFH and CFH-related proteins.
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4.4.3 Quantification of CRP
CRP levels were determined using a highly sensitive immunoturbidometric assay (Orion
Diagnostica, Espoo, Finland). CRP concentration was not available for three TT controls and one
CT control.
4.4.4 Purification of CFH402Y and CFH402H
The IgG fraction of goat antiserum to human CFH (Quidel) was precipitated with 18% Na2SO4. The
precipitate was washed with 18% Na2SO4 in phosphate buffered saline, pH 7.4 (PBS) and
resuspended in sodium carbonate buffer. The precipitate was then coupled to cyanogenbromide
(CNBr)-activated Sepharose 4B (Amersham Biosciences) according to the manufacturer's
instructions. Sera from ten controls with the TT genotype were pooled for isolation of CFH402Y
and sera from ten patients with the CC genotype were pooled for isolation of and CFH402H. Both
serum pools were incubated with Sepharose for 1 hour and the column was washed with 0.5 M
NaCl in PBS. The bound CFH proteins were eluted with the chaotropic agent sodium thiocyanate,
3M, and finally dialyzed against veronal-buffered saline. The purity of the proteins was checked by
SDS-PAGE and both silver staining and Western blotting. The concentrations of purified proteins
were determined by using absorbance measurements at 280 nm, the bicinchonic acid (BCA) Protein
Assay (Pierce) and silver staining.
4.4.5 Expression of recombinant CFH SCR5-7 and construction of CFH SCR5-7402H
variants
Recombinant CFH SCR5-7 constructs were generated as described by Jokiranta et al. (Jokiranta et
al. 2006) using specific primers for SCRs 5, 6 and 7 and pPICZ expression vectors. The Y402H
mutation was introduced to CFH SCR5-7 sequence by using the QuikChange Multi-Site
Mutagenesis Kit (Stratagene).
4.4.6 Binding of complement factor H to C-reactive protein
Maxisorp microtiter plates (Nunc) were coated with CRP (1 µg/ml, Calbiochem), whose purity was
confirmed with silver staining. After blocking, sera (1:1,000) from patients and controls, purified
CFH proteins or recombinant SCR5-7 variants were added. The plates were incubated for one hour
at 37°C and washed. Polyclonal goat anti-human CFH (1:5,000) was added. Peroxidase-conjugated
donkey anti-goat IgG diluted 1:10,000 was used as the secondary antibody. Chromogenic substrate
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and absorbance measurement at 492 nm were used for detection and results indicated as direct
optical density (OD) values. All the CFH-CRP binding experiments were repeated at least twice on
duplicate samples.
4.4.7 Binding of complement factor H to heparin
Binding of purified CFH proteins (CFH402Y and CFH402H) and respective SCR5-7 fragments to
heparin was analysed using heparin affinity chromatography in a high-performance liquid
chromatograph (HPLC) system (LaChrom L-7100, Hitachi). 10 µg of proteins were diluted in
1/2xPBS and applied to a heparin-Sepharose affinity column (HiTrap, Amersham Biosciences) at a
flow rate of 0.5 ml/min. The column was extensively washed with 1/2xPBS, and the bound proteins
were eluted using a linear salt gradient ranging from 75 to 500 mM NaCl, in a total volume of 10 ml
and at a flow rate of 0.5 ml/min.
4.4.8 Molecular modeling
The schematic molecular display model depicting binding between CFH and CRP presented in
Figure 4 (Study IV) is based upon the crystal structure of CRP (Shrive et al. 1996) and 10 copies of
nuclear magnetic resonance structures of the CFH SCR15-16 domain pair as display units (Barlow
et al. 1993). The model was created using InsightII 2000 (Accelrys Inc., San Diego, CA).
4.5 Statistical analysis
For skewed continuous variables the differences between groups were evaluated by non-parametric
tests, the Kruskal-Wallis H test and Mann-Whitney U test. The median and the 25% and 75%
quartiles are given as descriptive statistics. For the normally distributed continous variables
ANOVA test and two-tailed Student’s t-test were used. Post hoc comparisons between individual
groups were performed with the Games-Howell test as the variances of different groups were not
homogeneous. Genetic associations between the disease status and the SNPs were tested by means
of Chi-square test (and Fisher’s exact test, where necessary). Hardy Weinberg equilibrium was
tested in cases and controls separately, with the standard Chi-square test, to identify possible
genotyping errors.
Statistical analyses were performed with Tixel (version 8.1), a VBA-program for Excel (I), and with
SPSS (SPSS Inc., Chicago, Illinois; release 13.0; 2005 and 15.0; 2006) statistical software (II-V).
Odds ratios (OR) along with their confidence intervals were estimated with R scripts freely
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available on the Internet (R Packages Epitools, http://www.epitools.net). Furthermore, population
attributable risks (PAR) were estimated with Levin’s formula.
Logistic regression was used for estimating the marginal effects of the individual SNPs and
covariates (age, sex, smoking), and for dissecting potential statistical gene-gene and gene-
environment interactions. This was carried out with the SPSS Binary logistic regression modelling
procedure, in which stepwise backward variable selection procedure was used to screen out the
informative covariates from the uninformative. The coding for SNP genotypes (also called design
variables or dummy variables) followed the notation presented by Cordell and North et al. (Cordell
2002, North et al. 2005), to be able to assess the additive and dominance effects separately. The
stepwise backward conditional method was used for evaluating the significance of the explanatory
variables for the model.
The degree of biological interaction of the polymorphisms of the susceptibilty genes and smoking
was assessed by the departure-from-additivity model (Andersson et al. 2005), where two
dichotomous risk factors (carrier/non-carrier of a risk allele, smoker/non-smoker) were tested at a
time. Thus, four different risk factor combinations were generated with the no-risk-factors
combination as a reference. Relative risk due to interaction (RERI), attributable proportion due to
interaction (AP) and, synergy index (S) were calculated by an Excel program freely available on the
Internet (www.epinet.se).
The power of Study II was estimated by using the PS (version 2.1.31, 2004) software at
http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize, and the power of Study III
by the `power calculator` at http://calculators.stat.ucla.edu/powercalc/.
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5 RESULTS
5.1 Complement factor H gene (I-IV)
5.1.1 Association study (I)
In the complement factor H (CFH) gene the Y402H polymorphism (1277T>C) in exon 9
(rs1061170) was significantly associated with AMD in Finnish patients. We found that the
frequency of the AMD risk allele C was over-represented both in the familial cases compared to the
non-AMD (p=1.18x10-10, Chi-square test) or to the blood donor controls (p=1.85 x10-11) and in the
sporadic cases compared to the non-AMD (p=3.01x10-8) or to the blood donor controls (p=4.21
x10-8) (Tables 6 and 7). No difference existed in the C allele frequency between familial and
sporadic cases (p=0.419). Also, both familial and sporadic cases more often carried the
homozygous risk genotype (CC) than the non-risk genotype (TT) when compared to the non-AMD
controls (p=4.83 x 10-10; familial cases and p=4.83 x 10-10; sporadic cases) or to the blood donor
controls (p=2.64 x 10-10; familial cases and p=4.52 x 10-8; sporadic cases), but again, no difference
could be detected between familial and sporadic cases (p=0.814). Overall, the risk of AMD of the
homozygous patients was higher than that of the heterozygous patients, though a statistically
significant association was found also between AMD and the heterozygous genotype (CT) both in
familial and sporadic cases. (Table 7)
Table 6. Allele and genotype frequencies of the Y402H polymorphism of the complement factor H
(CFH) gene. C allele is the risk allele.
CFH  Y402H
Allele distribution      Genotype distribution
Case group (n) C (%) T (%) CC (%) CT (%) TT (%)
Familial cases (181) 66.3 33.7 45.3 42.0 12.7
Sporadic cases (154) 63.3 36.7 38.3 50.0 11.7
All AMD cases (335) 64.9 35.1 42.1 45.7 12.2
Non-AMD controls (105) 38.6 61.4 12.4 52.4 35.2
Blood donor controls (350) 44.6 55.4 20.0 49.1 30.9
62
Table 7. Association between AMD and the Y402H polymorphism of the complement factor H
(CFH) gene. AMD cases are compared to non-AMD controls (n=105) and to blood donor controls
(n=350). Shown are odds ratios (OR) with their 95% confidence intervals (95% CI) for case-
control comparisons. C allele is the risk allele.
                 Non-AMD controls (105)                 Blood donor controls (350)
CFH OR (95% CI) OR (95% CI)
Case group (n) (C versus T) (CT versus TT) (CC versus TT) (C versus T) (CT versus TT) (CC versus TT)
Familial cases (181) 3.13 (2.20-4.46) 2.22 (1.19-4.16) 10.1 (4.64-22.2) 2.45 (1.89-3.19) 2.07 (1.23-3.51) 5.50 (3.17-9.55)
Sporadic cases (154) 2.75 (1.91-3.94) 2.88 (1.49-5.57) 9.33 (4.10-21.3) 2.15 (1.63-2.83) 2.69 (1.52-4.73) 5.06 (2.75-9.28)
All AMD cases (335) 2.95 (2.14-4.06) 2.51 (1.46-4.31) 9.79 (4.76-20.1) 2.30 (1.85-2.86) 2.34 (1.54-3.57) 5.31 (3.35-8.40)
5.1.2 CFH Y402H polymorphism and AMD lesion characteristics (II)
Medians of lesion sizes of patients with neovascular AMD (n=164) were similar in the CFH Y402H
genotype groups, with lesion size of 8.15 mm2 in patients homozygous for the risk allele (CC,
n=58), 7.50 mm2 in heterozygous patients (CT, n=80), and 7.05 mm2 in those with the homozygous
non-risk genotype (TT, n=26), (p=0.599, Kruskal-Wallis H test). The corresponding medians of
CNV (classic and occult CNV together without serous PED and haemorrhage) lesion areas were
6.37 mm2, 5.00 mm2 and, 5.18 mm2, respectively (p=0.407).
To further analyse whether the genotype had an effect on the lesion size, patients were divided into
four quartiles according to the total lesion size. When the smallest or the largest quartile was
compared to the remaining three quartiles, no difference existed even in this comparison between
the genotypes. In a comparison of the CC and TT genotypes, the p-value was 0.916 when the largest
quartile (n=41) was compared to the three smallest (n=123) and 0.946 when the smallest quartile
(n=41) was compared to the three largest quartiles (n=123).
The CNV category was analysed only in lesions where the CNV lesion was 50% or more of the
total lesion area (n=144). These lesions were classified as predominantly classic, minimally classic,
or occult according to the Treatment of Age-related Macular Degeneration with Photodynamic
Therapy (TAP) study guidelines (TAP Study Group 1999). A tendency for the minimally classic
lesions to be more prevalent in patients with the CC genotype than with the TT genotype (p=0.105,
Chi-square) was seen, but generally, no statistically significant genotype differences could be
detected (Figure 7).
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Figure 7. Prevalence of the choroidal neovascularization (CNV) subtype categories (minimally
classic lesion, predominantly classic lesion, and occult lesion) in the different genotypes of the
complement factor H gene Y402H polymorphism, percentage within each genotype (CC, CT and
TT) and in CC and CT genotypes combined. Only patients with neovascular lesions 50% of the
total lesions are included.
Patients carrying the TT genotype had the RAP lesions more often (23.1%) than the CT (17.5%), or
CC (10.3%) patients, but the difference did not reach statistical significance (p=0.257, Fisher’s
exact test, TT compared to CT or CC). No difference in the proportion of patients with a serous
pigment epithelium detachment (PED) between the genotypes (TT: 15.4%, CT: 10.0%, and CC:
13.8%, p=0.528, Fisher’s exact test, TT compared to CT or CC) existed.
The age of onset of exudative AMD did not vary between CFH Y402H genotypes. The age of onset
of AMD in the first eye was rather similar in different genotypes both in unilateral (p=0.517,
Kruskall-Wallis H test) and bilateral (p=0.295) cases. The mean age of onset in the first eye was the
same at 74.8 years in TT patients and CC patients in unilateral cases and nearly the same at the age
of 73.3 (CC) and 73.0 (TT) in bilateral cases. Neither could a difference in the age of presentation
of the second eye between the genotypes (p=0.364) be found.
5.1.3 CFH Y402H polymorphism and outcome of photodynamic therapy (III)
Genotype of the CFH Y402H polymorphism did not determine, whether a patient was a “PDT-
responder” or a “PDT-non-responder”. Of the PDT-treated patients, 59 out of 88 (67.0%) were
“PDT-responders”: 18/26 (69.2%) of patients carrying the homozygous risk allele (CC), 34/50
(68.0%) of heterozygous patients (CT), and 7/12 (58.3%) of those with the normal genotype (TT)
(p= 0.520, Fisher’s exact test, TT compared to CT or CC).
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Median number (interquartile range) of PDT sessions of the “PDT-responders” was 3 (2) in all the
genotypes separately, as well as, in all the “PDT-responders”. In all the “PDT-non-responders”
median number of PDT sessions was 2 (1). A bias produced by the various number of PDT sessions
for the PDT-responders and for the PDT-non-responders (p=0.048 Mann-Whitney U test) was
excluded by performing an analysis where CFH Y402H genotypes were compared between the
PDT-responders with 2 PDT sessions and the PDT-non-responders with 2 PDT sessions
(p=0.406, Chi-square test, df=2) and between the PDT-responders with 3 PDT sessions and the
PDT-non-responders with 3 PDT sessions (p=0.182, Chi-square test, df=2). Thus, neither of these
comparisons showed any difference in genotypes between PDT-responders and PDT-non-
responders.
Within lesion type categories (predominantly classic, minimally classic, occult), no significant
difference was found in response rates to PDT between genotypes. In occult lesions, the PDT-
responder eyes with the CC genotype had received more treatments (3.5) than those with the CT
genotype (1.0) (p= 0.012, Mann-Whitney U test). The number of treatments of the patients with the
TT genotype (2.0) was between that with the CC genotype and that with the CT genotype, thus
suggesting that the difference was not true.
The final visual acuity was better and (p < 0.001) and the change of visual acuity smaller (p <0.001)
in all the PDT-responders than in all the PDT-non-responders. PDT-responders with the CC
genotype had a better final VA (20/80) than the patients with the CT genotype (20/200) (p=0.020,
Mann-Whitney U test), but again the TT genotype (20/125) was between the CC the CT genotypes.
Generally, no difference was detected in the final visual acuity or in change of visual acuity in the
“PDT-responders” or the “PDT-non-responders” between different genotypes of the CFH Y402H.
5.1.4 Functional analysis of complement factor H (IV)
5.1.4.1 Location of C-reactive protein and complemen factor H in drusen
The expression of CFH and CRP were analysed by confocal immunofluorescence microscopy. In
two representative cases, CFH was shown to be present throughout the drusen in individuals with
either the TT or CC genotype, and CRP was present in small spheroid particles inside the drusen.
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5.1.4.2 Reduced binding affinity of CFH402H to C-reactive protein but binding to heparin not
affected
An ELISA assay was set up by coating plate wells with CRP to analyse the binding of the different
variants of the complement factor H to CRP. Binding of serum-derived CFH, purified CFH, and
recombinant CFH SCR5-7 fragments to CRP were analysed. A significantly reduced binding of
CFH to CRP was found in the sera of AMD patients homozygous for the Y402H risk allele (CC)
(OD492: 0.369±0.102, n=20) when compared to patients with the non-risk (TT) genotype (OD492:
0.532±0.102, n=16, p=4.9x10-4) (ANOVA). A similar difference in the sera of healthy controls
indicated that the functional difference in CRP binding is genotype, not disease, associated (CC
controls: OD492: 0.324±0.098, n=9, TT controls: OD492: 0.697±0.199, n=14, p=1.0x10-4). Binding of
serum CFH to CRP also was reduced in the heterozygous patients (CT). Also, when data from the
patient and control groups were pooled according to genotype, a significant difference in CFH
binding to CRP was observed (F=27.4, p=1.1x10-9) with the greatest difference between the CC
(OD492: 0.355±0.101, n=29) and TT genotypes (OD492: 0.609±0.173, n=30, p=3.9x10-8) and
between the CT (OD492: 0.499±0.100, n=20) and TT genotypes (p=4.2x10-4), but the difference
between CC and CT genotypes was also significant (p=6.8x10-3) (ANOVA). By measuring CFH
concentrations of the samples, varying CFH levels as the cause for these results were excluded.
When data of AMD patients were pooled regardless of genotype (OD492: 0.445±0.129, n=46) and
compared with pooled control data (OD492: 0.518±0.214, n=33), no significant difference in CFH
binding to CRP was observed (p=0.062) (Student’s t-test). Binding of purified full length CFH402H
protein to CRP (OD492: 0.470±0.033) was significantly weaker than that of the CFH402Y protein
(OD492: 0.668±0.103, p=0.034) (Student’s t-test). An even more marked difference was observed
between the two recombinant fragments of CFH in binding to CRP than using the full-length
proteins.
Heparin-Sepharose affinity chromatography was used to assess the binding of the two full-length
CFH variants, CFH402Y derived from controls and CFH402H derived from patients, to heparin. Both
protein variants eluted from the column at the same ionic strength indicating that the CFH Y402H
variation does not markedly affect the binding of CFH to heparin. Similar results were obtained
using recombinant fragments of CFH SCR5-7 containing either the 402Y or 402H residues.
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5.2 Other candidate genes (I,V)
5.2.1 LOC387715/HTRA1 locus
The two SNPs (LOC387715 rs10490924 and HTRA1 rs11200638) are located only 6.1 kb from
each other and are therefore in almost complete linkage disequilibrium. Due to the close proximity
of the two genes we observed only 5 genotypes out of 787 inconsistent with perfect LD in these two
genes. We decided to focus on the LOC387715 gene, since there is cumulating evidence for
LOC387715 A69S to be the actual causal variant in AMD (Kanda et al. 2007).
In our Finnish patient material, both familial and sporadic cases had the AMD-associated
LOC387715 A69S risk allele T more often than the non-AMD (p= 2.32 x 10-14; familial cases and
p=1.54 x10-8; sporadic cases, Chi-square test) or the blood donor controls (p=6.11 x 10-18; familial
cases and p=6.90 x10-9; sporadic cases) (Tables 8 and 9). Both familial (p =2.73x10-12) and sporadic
cases (p=9.95x10-7) also carried more often the LOC387715 risk genotype TT than the GG
genotype when compared to non-AMD controls, or to blood-donor controls (p=1.35x10-15; familial
cases and p=8.48x10-7; sporadic cases) (Tables 8 and 9). No differences between the genotype
frequencies of familial and sporadic cases were detected (p=0.09).
Table 8. Allele and genotype frequencies of the A69S polymorphism of the LOC387715 gene. T
allele is the risk allele.
LOC387715
Allele distribution      Genotype distribution
Case group (n) T (%) G (%) TT (%) GT (%) GG (%)
Familial cases (181) 51.4 48.6 27.6 47.5 24.9
Sporadic cases (151) 43.4 56.6 17.9 51.0 31.1
All AMD cases (332) 47.7 52.3 23.2 49.1 27.7
Non-AMD controls (105) 19.5 80.5 2.9 33.3 63.8
Blood donor controls (350) 24.7 75.3 6.4 36.5 57.1
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Table 9. Association between AMD and the A69S polymorphism of the LOC387715 gene. AMD
cases are compared to non-AMD controls (n=105) and to blood donor controls (n=350). Shown
are odds ratios (OR) with their 95% confidence intervals (95% CI) for case-control comparisons. T
allele is the risk allele.
                 Non-AMD controls (105)                 Blood donor controls (350)
LOC387715 OR (95% CI) OR (95% CI)
Case group (n) (T versus G) (TG versus GG) (TT versus GG) (T versus G) (TG versus GG) (TT versus GG)
Familial cases (181) 4.34 (2.93-6.53) 3.63 (2.12-6.33) 23.3 (7.90-104.2) 3.23 (2.47-4.22) 2.98 (1.96-4.58) 9.77 (5.48-18.0)
Sporadic cases (151) 3.14 (2.10-4.78) 3.11 (1.81-5.43) 12.1 (3.95-55.1) 2.34 (1.76-3.11) 2.55 (1.68-3.93) 5.08 (2.68-9.74)
All AMD cases (332) 2.98 (2.05-4.40) 3.37 (2.09-5.52) 17.7 (6.23-76.9) 2.79 (2.22-3.51) 2.77 (1.98-3.89) 7.39 (4.42-12.8)
5.2.2 Complement component 3 gene
The risk allele G of the R102G variant, corresponding to the electrophoretic protein variant C3F
(fast), in exon 3 of complement component 3 (C3) was associated with AMD in familial cases when
compared to non-AMD controls (p=0.008, Chi-square test) or to blood donor controls (p=0.039),
and in all AMD cases when compared to non-AMD controls (p=0.039) (Tables 10 and 11). The
heterozygous risk genotype CG was also detected more often in familial cases than in non-AMD
(p=0.013) or in blood donor controls (p=0.049). However, the difference in the frequency of the
homozygous risk genotype GG between familial cases and controls did not to reach statistical
significance since there were too few GG cases in our material, but the trend is clear: there seems to
be higher OR for homozygotes (OR 2.41; non-AMD controls and OR;1.64, blood donor controls)
than for heterozygous cases (OR 2.01; non-AMD controls and 1.48; blood donor controls).
Table 10. Allele and genotype frequencies of the R102G polymorphism of the complement
component 3 (C3) gene. G allele is the risk allele.
C3
Allele distribution      Genotype distribution
Case group (n) G (%) C (%) GG (%) CG (%) CC (%)
Familial cases (181) 24.9 75.1 5.5 38.7 55.8
Sporadic cases (151) 18.5 81.5 4.0 29.1 66.9
All AMD cases (332) 22.0 78.0 4.8 34.3 60.9
Non-AMD controls (105) 15.2 84.8 2.8 24.8 72.4
Blood donor controls (350) 19.3 80.7 4.0 30.6 65.4
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Table 11. Association between AMD and the R102G polymorphism of the complement component 3
gene. AMD cases are compared to non-AMD controls (n=105) and to blood donor controls
(n=350). Shown are odds ratios (OR) with their 95% confidence intervals (95% CI) for case-
control comparisons. G allele is the risk allele.
                 Non-AMD controls (105)                 Blood donor controls (350)
C3 OR (95% CI) OR (95% CI)
Case group (n) (G versus C) (GC versus CC) (GG versus CC) (G versus C) (GC versus CC) (GG versus CC)
Familial cases (181) 1.83 (1.18-2.90) 2.01 (1.18-3.51) 2.41 (0.70-11.62) 1.39 (1.02-1.88) 1.48 (1.01-2.17) 1.64 (0.68-3.82)
Sporadic cases (154) 1.26 (0.79-2.05) 1.27 (0.72-2.27) 1.47 (0.36-7.56) 0.96 (0.67-1.34) 0.93 (0.61-1.42) 0.99 (0.34-2.58)
All AMD cases (335) 1.56 (1.04-2.41) 1.64 (1.00-2.75) 1.92 (0.61-8.82) 1.18 (0.91-1.54) 1.21 (0.87-1.67) 1.30 (0.62-2.79)
5.2.3 Interaction analyses of the susceptibility factors
Two-locus joint ORs of the CFH Y402H and the LOC387715 A69S polymorphisms as well as the
three-locus joint risks of the CFH Y402H, the LOC387715 A69S, and the C3 R102G
polymorphisms were also analysed. The risk of AMD for a carrier of both homozygous risk
genotypes CC (CFH) and TT (LOC387715) was 27-fold (p=1.66x10-12) when compared to a carrier
of a non-risk genotype TTGG, with all the other joint OR:s ranging from 2 to 21 (Table 12). When
individuals carrying at least one risk allele in each locus were compared to individuals with no risk
alleles at any of the loci the risk of AMD was 18-fold (Figure 8). The joint OR for three loci and
smoking was 74.3 (95% CI 10.81-2124, p=1.54 x 10-7).
Table 12. Two-locus odds ratios (OR and 95% confidence intervals [95%CI]) for different
genotypic combinations of the complement factor H gene rs1061170 (genotypes CC/CT/TT) and the
LOC387715 rs10490924 (genotypes TT/TG/GG). Eight genotype combinations are compared to the
non-risk genotype combination TTGG. Risk alleles are C (CFH) and T (LOC387715). All patients
with AMD (n=332) are compared to blood donor controls (n=350).
Genotypic
combination of Number of
CFH  and LOC387715 risk alleles OR (95%CI)
TTGG 0 1.00
CTGG 1 2.31 (1.09-5.26)
CCGG 2 8.83 (4.11-20.61)
TTTG 1 2.89 (1.20-7.31)
CTTG 2 8.48 (4.19-18.84)
CCTG 3 14.41 (6.67-33.85)
TTTT 2 21.38 (6.26-91.39)
CTTT 3 17.35 (7.03-46.92)
CCTT 4 26.57 (9.71-83.25)
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Figure 8. Odds ratios (OR) with their 95% confidence intervals (95%CI) of three-locus risks for
combinations of the risk allele carriers of the complement factor H (rs1061170), the LOC387715
(rs10490924) and the C3 (rs2230199) genes. Seven combinations are compared to individuals who
carry no risk allele. Patients with AMD (n=332) are compared to blood donor controls (n=350).
A highly significant (p<0.001) additive gene effect for the two main loci, LOC387715 and CFH,
was found in the logistic regression model. Their effects seem to be of the same size. The C3
additive effect is slightly weaker with an effect size of 2.2, though it also is statistically siginificant.
No dominance effect was seen for any of the loci (CFH, LOC387715, C3).
In logistic regression framework we did not detect an independent effect of smoking in our material.
Neither could an interaction between CFH Y402H or LOC387715 A69S and smoking be
demonstrated. Instead, environment-environment (ExE) and gene-environment (GxE) type
interactions were suggested for sex x smoking (p=0.043) and C3 x smoking (p=0.086). Combined
to a 3-way interaction, C3 x sex x smoking (p=0.016), the 2-way interaction C3 x smoking,
disappeared. The sex x smoking interaction term, however, preserves its borderline significance
(now, p=0.065). Explanations for this rather unexpected complexity showed up in further stratified
analyses. In sex x smoking interaction the risk of AMD was statistically significantly higher in an
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ever-smoker women (p=3.60 x 10-4) than in a never-smoker women, whereas in men the difference
was borderline (p=0.054). Thus, the effect of smoking is more pronounced in women, which also
explains the significance of the sex x smoking interaction, and at the same time explains why we
did not get an independent main effect for smoking alone. In the C3 x smoking interaction, smoking
seems to have a significant effect in homozygous normal genotype CC (p=1.30 x 10-4), but not in
G-carrying genotypes (p = non significant) (although the trend is the same). In the never-smokers,
G allele predisposes for AMD whereas in ever-smokers the effect of the G allele is virtually
indistinguishable. In C3 x sex x smoking interaction we see highest OR for ever-smoker women
with genotype CC (p=1.93 x 10 -4), and non-significant effects in G-carrying genotypes (p=0.39)
(though the trend is the same, that is, smoking predisposes to AMD in all genotype x sex classes,
OR:s circa 2) (Table 13). Evidently, the final model explains the variation in the individuals’
disease risks quite well; Nagelkerke R Square = 0.431.
Table 13. Odds ratios (OR) with their 95% confidence intervals (95%CI) for the gene-environment
interaction of the R102G polymorphism of the complement component 3 (C3) gene, sex and
smoking. AMD cases (332) are compared to the non-AMD controls (n=105). G allele is the risk
allele. Never/ever-smoker status is based on the information whether a study participant had
smoked < one pack-year (never-smoker), or > one pack-year (ever-smoker) in his/her lifetime.
Comparison  OR (95%CI)
1 Ever-smoker female versus 4.68 (1.95-14.1)
never-smoker female
2 Ever-smoker male vs. 2.57 (0.99-6.86)
never-smoker male
3 C3  CC-carrier+ever-smoker versus 4.18 (1.97-10.1)
C3  CC-carrier+never-smoker
4 C3  G-carrier+ever-smoker versus 1.94 (0.79-5.33)
C3  G-carrier+never-smoker
5 C3  G-carrier+never-smoker versus 1.80 (1.03-3.24)
C3  CC carrier+never-smoker
6 C3  G-carrier+ever-smoker versus 3.50 (1.56-9.02)
C3  CC-carrier+never-smoker
7 C3  CC-carrier+ever-smoker+female versus 8.55 (2.45-58.5)
C3  CC-carrier+never-smoker+female
8 C3  G-carrier+ever-smoker+female versus 1.89 (0.55-9.12)
C3  G-carrier+never-smoker+female
9 C3  CC-carrier+ever-smoker+male versus 2.81 (0.83-10.2)
C3  CC-carrier+never-smoker+male
10 C3  G-carrier+ever-smoker+male versus 2.05 (0.40-10.6)
C3  G-carrier+never-smoker+male
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Interestingly, an interaction between two major susceptibilty genes, CFH Y402H and LOC387715
A69S, was found. The interaction was demonstrated in models assessing both the biological
(departure-from-additivity) and the statistical (p=0.057) (logistic regression model) interaction. In
the departure-from-additivity model (by Andersson et al 2005) the attributable proportion due to
interaction of the loci was 70% (95%CI 51-89%) and S, the synergy index 3.79 (95%CI 1.82-7.89)
(Figure 9).
The estimated population attributable risk (PAR) “reflects the prediction of how much of the
disease would be eliminated from the case-control population if the high risk genotype were not
present” (Gorin 2007). For a carrier of the risk alleles of CFH (rs1061170), LOC387715
(rs10490924), and C3 (rs2230199) the PARs were 58.2%, 51.4%, and 5.8%, respectively (using
blood donor controls as reference group). The joint PAR for the three loci was 63%. The summary
PAR is less than the sum of the three single PARs, since carrying a risk allele in one locus does not
exclude carrying a risk allele also in the other locus (Schmidt et al. 2006). The PAR for smoking
alone was 47.7%. Since non-AMD controls were used as a reference group this PAR cannot be
interpreted as a true populationwise figure.
Figure 9. Excel sheet from www.epinet.se, showing the results of biological interaction calculations
(interaction between LOC387715 A69S [LOC] and CFH Y402H [CFH]) performed as Anderson et
al. 2005.
72
5.2.4 Elongation of very long chain fatty acids-like 4 (I) and hemicentin-1 genes (I)
In the ELOVL4 gene (I) no association between AMD and the M299V polymorphism in exon 6
(rs3812153) was detected. Interestingly, none of familial cases (n=181), sporadic cases (n=154), or
non-AMD controls (n=105) had the homozygous risk genotype (GG). No difference in the genotype
or allele frequencies existed in familial cases compared to non-AMD controls (p=0.451;genotype
and p=0.474; allele, Chi-square test) or to blood donor controls (n=350) (p=0.792;genotype and
p=0.874;allele) or in sporadic cases compared to non-AMD controls (p=0.593;genotype and
p=0.607;allele) or to blood donor controls (p=0.168;genotype and p=0.093;allele).
None of the patients or controls was carrying the Q5345R variant of exon 104 of the hemicentin-1
gene (I).
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6 DISCUSSION AND CONCLUSIONS
Significant advances have been made during the past few years in the field of molecular genetics of
AMD although the pathogenesis is still poorly understood. The interplay between multiple genes
and environmental risk factors in complex (multifactorial) disorders makes them a challenging
research subject. AMD has often been presented as an example of a success story in terms of
revealing the genetics of a complex disease (Amos 2007, Ropers 2007). Recently, a remarkable
discussion has also been going on whether genome-wide linkage studies are the correct tools for
detecting genes for complex diseases. Collecting patient material with a sufficient number of
families for linkage studies is a slow and demanding task yet the material and methods still may be
incapable of identifying genes involved in the pathogenesis of a common disease. However, in
AMD, several genome-wide scans showed repeatedly linkage to the long arms of chromosomes 1
and 10 (Weeks et al. 2001, Majewski et al. 2003, Abecasis et al. 2004, Iyengar et al. 2004, Weeks et
al. 2004, Fisher et al. 2005, Barral et al. 2006), which was the basis for later association studies that
finally revealed the two major risk variants, Y402H polymorphism of the CFH gene on 1q32, and
then the LOC387715/HTRA1 locus on 10q26. Three out the four first studies reporting the CFH
Y402H polymorphism (Edwards et al. 2005, Hageman et al. 2005, Haines et al. 2005) and the first
study reporting the LOC387715/HTRA1 locus (Jakobsdottir et al. 2005) exploited the prior results
of genome-wide linkage analyses and performed a focused genotyping with SNPs flanking only
these regions, 1q32 and 10q26. On the other hand, CFH Y402H polymorphism was also
successfully found in a study using a whole-genome association approach in a relatively small
patient sample. A total of 96 cases and 50 controls from AREDS study were genotyped with 16,204
SNPs of which only two had different frequencies between case and control populations. These two
SNPs lay on the intron of the complement factor H gene, and on further sequencing of all the exons
of CFH gene, an association between the CFH Y402H polymorphism and AMD was finally found
(Klein et al. 2005). Thus, both genome-wide linkage analysis and the whole-genome association
approach were useful tools in detecting susceptibility genes of AMD. The reasons contributing to
the success have been accurate definition of the phenotype and the existence of major loci at 1q32
and 10q26. As mentioned above, this was a significant achievement not only in the genetics of
AMD but also in the genetics of complex diseases in general. This forcefully guided research
projects, including ours.
The population of Finland represents a genetic isolate. It is characterized, on one hand, by an
enrichment of certain rare monogenic diseases, called the Finnish disease heritage and, on the other
74
hand, lacking many Mendelian disorders common in Caucasians (Norio 2003). We found that the
CFH Y402H polymorphism is as strong risk factor for AMD in the Finnish as in several other
Caucasian populations. Thus, the possible defect in CFH may contribute to pathogenesis of AMD
similarly in the Finnish population as it is in less isolated Caucasian populations. The complement
system is a critically important part of innate immunity and CFH plays a vital role in it by
protecting host cells from the excessive attack of complement. Regarding this, it is understandable
that CFH is universal in nature and its defects may be destructive irrespective of a population. On
the other hand, the “common disease, common variant” hypothesis, which means that a relatively
common allele predisposes to a common disease, appeares to be proved in AMD (Chakravarti 1999,
Reich et al. 2001).
Drusen, the hallmarks of early AMD, have been known to contain components of the complement
system, including C3, complement factor H, and membrane attack complex (MAC), for a relatively
long time, but recently the complement system has been reported to be involved in the growth of
experimental choroidal neovascularization (CNV), as well (Bora et al. 2005, Bora et al. 2006).
Further, C3 and MAC were deposited in experimental murine laser induced CNV (Bora et al. 2005).
The complement system was central for the expression of vascular endothelial growth factor
(VEGF), transforming growth factor-2 (TGF-2), and -fibroblast growth factor (-FGF) in the
experimental CNV lesions (Bora et al. 2005), and by inhibiting the alternative pathway of the
complement system, the CNV formation could be abolished (Bora et al. 2006). Based on these data,
we had generated a hypothesis that the CFH Y402H risk polymorphism would favour a more
aggressive phenotype in neovascular AMD, but it turned out not to be the case in our studies.
Genotype frequencies were similar in patients with predominantly classic, minimally classic, or
occult CNV, and neither could an effect of CFH Y402H polymorphism on CNV lesion size be
detected. Two independent groups have published contradictory results. They reported that a person
with the risk allele had more often predominantly classic CNV lesions than other subtypes.
(Brantley et al. 2007a, Wegscheider et al. 2007). The sizes of the patient materials in these studies
were the same as in ours, and the angiograms were analysed at the same moment, namely at the
initial presentation of active neovascularization. The criteria of the Treatment of Age-Related
Macular Degeneration with Photodynamic Therapy (TAP) study were used for classification in two
of the studies (criteria not stated in Brantley et al.) and the mean age of the patients was nearly the
same. Thus, the reason we did not detect any difference in the CNV lesion types remains so far
unclear, raising the question of whether other genetic factors, like variants in VEFG gene, may have
an effect on CNV lesion characteristics (Churchill et al. 2006). However, similarly to us, Brantley et
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al. could neither find any differences in CNV lesion sizes between the CFH Y402H genotypes,
though they used greatest linear dimension (GLD) and we used area of lesion as our size criterion
(Brantley et al. 2007a). When Brantley et al. further studied whether the Y402H polymorphism had
an effect on the outcome of bevasizumab (Avastin®) therapy, they found that different genotype
groups had similar frequencies of the predominantly classic lesions and, interestingly, they now
found that the GLD was largest (p=0.02) in patients carrying the TT genotype (Brantley et al.
2007b).
The complement cascade has been shown to be a central element in the tissue response to
experimental PDT in cancerous lesions. Complement is activated in experimental PDT, and the
effect of PDT can be modified by complement activators or inhibitors (Korbelik 2006, Korbelik et
al. 2007). Yet we failed to detect any overall difference in response to PDT in neovascular AMD
lesions between different genotypes of the CFH Y402H polymorphism. These results can be
interpreted by the belief that CFH Y402H polymorphism is an unlikely modulator of the response
to acute tissue destruction (as caused by PDT) in the central choriocapillaris and the macula. This
suggests that the increased risk for AMD is caused by a deficiency in a very specialized function of
CFH unrelated to general damage control. So far, only one other group has reported CFH Y402H
polymorphism and the effect of PDT (Goverdhan et al. 2007). In a study from United Kingdom,
where 27 PDT-treated patients were evaluated, patients carrying the risk allele C seemed to need
PDT more frequently (OR 2.16, 95% CI [1.19-3.93], p=0.011), and visual loss after PDT was more
frequent in patients with the CC (n=13) when compared to TT (n=2) genotype (0.038) (Goverdhan
et al. 2007). Considering this small data set, no conclusions can be made, about whether a
difference between the genotypes of CFH Y402H in PDT-response really exists.
The role of complement in the pathogenesis of AMD has been suggested long before the major
finding of the CFH Y402H polymorphism, based on the composition of drusen deposits (Mullins et
al. 2000, Hageman et al. 2001). Complement factor H has an essential role in the regulation of the
alternative pathway of the complement system. The Y402H risk variant is located in the short
consensus repeat (SCR) 7 of CFH protein, which possesses a binding site for CRP. Study IV
showed that the homozygous (CC) and heterozygous (CT) risk genotypes of CFH Y402H had a
lower binding affinity to CRP than the TT variant, which has been later confirmed by Skerka et al.
(Skerka et al. 2007). Serum CRP level is elevated in AMD and the protein is present in AMD
lesions (Seddon et al. 2004, Seddon et al. 2005b). Deposition of CRP on the site of cellular damage
and debris may, among other things, facilitate activation of the classical complement pathway,
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resulting in C3 binding and all the consequences of complement activation. The binding of CFH to
CRP might contribute to controlling such a process. Attachment of CFH to CRP would help in
concentrating CFH at sites of CRP-related complement activation. The CRP-bound CFH would
then contribute to inactivation of surface bound C3 to C3bi, preventing further steps in the
complement cascade. C3bi is recognized by the complement receptor type 3 (CR3), CD11b/18, on
phagocytes (Rothlein et al. 1985) and activation of CR3 leads to anti-inflammatory type cytokine
response, and excessive inflammatory reaction and tissue damage is thus avoided (Wright et al.
1983, Yamamoto et al. 1984). However, at this point, there is insufficient evidence to confirm such
a scenario and little experimental data on the interaction of CRP and CFH in retinal lesions exist.
The observed difference in the binding affinity to CRP between genotypes was irrespective of case-
control status, which indicates that other genetic/environmental risk factors or protective factors
play a role in pathogenetic pathways of AMD.
As well as the CFH Y402H, the LOC387715 A69S polymorphism almost certainly contributes to
AMD pathogenesis.The function of LOC387715 is unknown, although just recently it was found on
the mitochondrial outer membranes (Kanda et al. 2007). This may give hints of its function in the
pathogenesis of AMD, since mitochondria have been shown to play an important role in aging
processes (Harman 1981). In addition, already two decades ago it was noticed that mitochondria
activate complement (Giclas et al. 1979). A risky, but attractive, hypothesis thus is that CFH and
LOC388715 would be involved in a common pathogenetic pathway. In the Finnish population, the
A69S LOC387715 was seen as a strong risk factor for AMD as in other populations (Jakobsdottir et
al. 2005, Rivera et al. 2005, Conley et al. 2006, Schmidt et al. 2006, Ross et al. 2007, Schaumberg
et al. 2007, Tanimoto et al. 2007).
The significance of the complement factor 3-gene polymorphism is still to be resolved. Earlier, two
independent groups found an association to AMD that was, however, weaker than that with the
CFH and the LOC387715 (Maller et al. 2007, Yates et al. 2007). In the C3 locus, we detected an
additive gene effect that was weaker than that of LOC387715 or CFH.
No associations between AMD and polymorphisms in the hemicentin-1 and the elongation of very
long chain fatty acids-like 4 (ELOVL4) gene were detected in our patient material. As the
hemicentin-1 gene codes a large extracellular member of the immunoglobulin superfamily (Schultz
et al. 2003b) and variations in the ELOVL4 gene have previously been identified in autosomal
dominant macular dystrophy (Bernstein et al. 2001, Edwards et al. 2001, Zhang et al. 2001,
Maugeri et al. 2004), an association would have been plausible. However, a risk variant of
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hemicentin-1 gene has been found only in one large US family (Schultz et al. 2003b) and one
positive association of ELOVL4 with AMD (Conley et al. 2005) could not have been replicated in
other populations either (Conley et al. 2006, DeAngelis et al. 2007). Possibly, variants of these three
genes contribute only to a relatively small percentage of AMD cases.
Interestingly, to the best of our knowledge, for the first time (Jakobsdottir et al. 2005, Rivera et al.
2005, Schmidt et al. 2006), a statistical interaction between the CFH Y402H and the LOC387715
A69S polymorphisms was detected in our study using both multiplicative (logistic regression)
model and departure-from-additivity model. Smoking and these two variants seemed, however, to
be independent risk factors, which, instead, was in line with the majority of earlier results (Conley
et al. 2006, Sepp et al. 2006, DeAngelis et al. 2007, Ross et al. 2007, Scott et al. 2007, Shuler et al.
2007a, Wang et al. 2007b). The independent contribution of smoking and CFH was a little bit
surprising, since smoking is a major environmental risk factor for AMD (Delcourt et al. 1998,
Smith et al. 1996, Seddon et al. 2006,), and cigarette smoke has been shown to activate the
complement system (Robbins et al. 1991). Smoking also increases serum CRP concentrations
(Yanbaeva et al. 2007) and further, an impaired binding of CRP to the CC or CT variants of CFH
(Y402H) was shown (Skerka et al. 2007).
Surprisingly, a C3 x sex x smoking interaction was found with the highest OR for a women with the
non-risk genotype of C3 who has smoked over 1 pack-year. C3 plays a crucial role in all the three
pathways of the complement system (Walport 2001), is a component of drusen deposits (Hageman
et al. 2005), and activation of alternative pathway of complement system by cigarette smoke has
been shown to be mediated by C3 (Kew et al. 1985, Kew et al. 1987). Hence, it is reasonable to
think that a true C3 x smoking interaction may exist. However, further studies in different
populations are warranted to confirm both the association between C3 R102G and AMD and the
aforementioned gene-environment interaction.
The estimated population attributable risks (PAR) for a carrier of the risk allele of CFH Y402H,
LOC387715 A69S, and C3 R102G were 58.2%, 51.4%, and 5.8%, respectively, and the joint
attributable risk for the three loci was 63%. The risks are in agreement with previous studies with
the PARs for CFH Y402H ranging from 43 to 68 % (Haines et al. 2005, Jakobsdottir et al. 2005,
Baird et al. 2006, Conley et al. 2006, Schmidt et al. 2006) and for LOC387715 A69S ranging from
36 to 57% (Jakobsdottir et al. 2005, Conley et al. 2006, Schmidt et al. 2006). Instead, the PAR for
C3 R102G in Yates et al. was higher (22%) (Yates et al. 2007) than that of ours (5.8%). It was
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hypothesized that the effect of C3 is diluted in our data by the stronger effect of CC genotype in
ever-smoking women (C3 x sex x smoking).
Our knowledge of the genetics of AMD has thus increased considerably in the past few years, but
the benefits to clinical practice are still limited. Since no genotype-specific preventive therapy or
AMD is available at the moment and it is unknown, whether the genetic profile had a true effect on
therapy outcomes, the presymptomatic genetic testing gives no advantage for AMD patients yet.
Despite this, it is evident that the risk of AMD of an individual carrying all the three risk alleles
(CFH Y402H, LOC387715 A69S and C3 R102G) is substantial. Although these genetic
observations do not unveil the exact mechanisms of AMD, they will certainly help in focusing
future cell biological and clinical studies. Most likely, this knowledge will open up avenues for the
development of novel therapies for AMD.
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